Differential knockout of allele of heterozygous elane gene

The CRISPR-based method targets and inactivates dominant mutant alleles of the ELANE gene to treat SCN, offering a more effective and safer alternative to current therapies by reducing neutropenia severity without the risks of long-term side effects.

JP2024160277AInactive Publication Date: 2024-11-13EMENDOBIO INC
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2024125705
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2018-10-09
Filing Date
2024-08-01
Publication Date
2024-11-13
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current treatments for severe congenital neutropenia (SCN), such as G-CSF therapy and hematopoietic stem cell transplantation, have limitations including long-term side effects and the risk of developing myelodysplastic syndrome or leukemia, and there is a need for a more targeted approach to inactivate dominant mutant alleles causing the condition.

Method used

The method employs CRISPR nuclease and guide RNA molecules to selectively target and inactivate mutant alleles of the ELANE gene associated with SCN or cyclic neutropenia by introducing double-strand breaks, allowing for the expression of functional proteins while eliminating the disease-causing alleles.

Benefits of technology

This approach effectively reduces the severity of neutropenia by inactivating dominant mutant alleles, potentially avoiding long-term side effects of existing treatments and providing a more targeted therapeutic option for patients with SCN or cyclic neutropenia.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024160277000042
    Figure 2024160277000042
  • Figure 2024160277000043
    Figure 2024160277000043
  • Figure 2024160277000044
    Figure 2024160277000044
Patent Text Reader

Abstract

To provide a method for inactivating a variant allele of a neutrophil elastase gene (ELANE gene) having variation related to severe congenital neutropenia (SCN) or cyclic neutropenia (CyN), of a cell.SOLUTION: A method for activating a variant allele of an ELANE gene having variation related to SCN or CyN, where a cell is heterozygous in one or a plurality of polymorphic site selected from a specific SNP group including rs104l4837 or the like, includes introducing a composition including a first RNA molecule, which includes a sequence encoding CRISPR nuclease or CRISPR nuclease and a guide sequence part having 17 to 20 pieces of nucleotides, into a cell. A composite of CRISPR nuclease and the first RNA molecule affects the double-strand cleavage in a variation allele of an ELANE gene.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] This application is a continuation of U.S. Provisional Application No. 62 / 743,309, filed October 9, 2018. U.S. Provisional Application No. 62 / 723,941, filed August 28, 2018; This application claims the benefit of U.S. Provisional Application No. 62 / 667,536, filed on May 6, the contents of each of which are incorporated herein by reference.

[0002] Throughout this application, various publications are referenced, including by parenthetical references. The disclosures of all publications mentioned in this application are incorporated herein by reference in their entirety, including without limitation the art to which this invention pertains and the present invention. No. 6,099,723, filed in its entirety to provide additional description of features of the art that can be utilized. No. 60 / 699,493, filed on Oct. 1, 2003, which is incorporated by reference into this application.

[0003] A reference to an array list This application is filed under the title "190506_90522-A-PCTjSequenceJListi The nucleotide sequence present in the file named "ng_ADR.txt" is This file is 249 kilobytes in size and is compatible with MS-Windows. 2 in IBM-PC machine format with compatible operating system Text created on May 3, 2019 and filed as part of this application on May 6, 2019 included in the list file. [Background technology]

[0004] The human genome contains insertions and deletions, copy number differences in repetitive sequences, and single nucleotide polymorphisms (SNPs). There are several types of DNA variations, including: SNPs, which are variations of a single base (adenine (A), thymine (T), cytosine (C), or guanine (G)) between human subjects or within an individual It is a variation in DNA sequence that occurs when a pair of chromosomes differs. DNA variations of a type are useful for pinpointing genetic traits or studying disease causation. It has become a focus of the research community, either as a researcher or as a potential cause of genetic disorders. SNPs are generally considered to be benign and not disease-causing.

[0005] Genetic disorders are caused by one or more abnormalities in the genome. Recessive disorders may be considered either "non-occurring" or "recessive." Recessive disorders are those that present Disorders that require two copies (i.e., two alleles) of an abnormal / missing gene to occur In contrast, dominant genetic disorders involve normal (functional / healthy) genes or A dominant gene or group of genes is involved in a gene or group of genes that show dominance over a group of genes. In certain genetic disorders, the genetic information required to cause or contribute to the symptoms of a particular genetic disorder is Only one copy (i.e., one allele) of the abnormal defective gene is required. Mutations include, for example, altered gene products that have a new molecular function or a new pattern of gene expression. Gain-of-function mutations include those with a dominant-negative mutation. An example of a dominant-negative mutation is when one allele mutates and becomes nonfunctional. The single wild-type allele remaining is sufficient for a specific cellular function to produce a necessary protein. Other examples include genes that act antagonistically to the wild-type allele. Dominant negative mutations having gene products are included.

[0006] Neutropenia Neutropenia is defined as a decrease in the absolute number of circulating neutrophils, usually in peripheral blood. It is diagnosed by measuring the absolute neutropenia count (ANC). The severity of neutropenia varies depending on the AN. If C is 1000-1500 / μL, it is mild, and if ANC is 500-1000 / μL, it is Moderate or severe if ANC < 500 / μL (Boxer 201 2).

[0007] Neutropenia can be classified as congenital (genetic) or acquired. The two main types of neutropenia, usually autosomal dominant, are cyclic neutropenia (CyN) and and severe congenital neutropenia (SCN). Cyclic neutropenia is when neutrophil counts drop below normal levels. Severe congenital neutropenia (S CN) is characterized at birth by a very low ANC (500 / mT) and promyelocytic / myelocytic serotonin levels. It is characterized by the cessation of hematopoietic maturation in the bone marrow at this stage and the early onset of bacterial infections. (Carlsson et al. 2012; Horwitz et al. 2013) .

[0008] SCN is diagnosed by measuring very low ANC in the blood and examining bone marrow aspirates to detect arrest of bone marrow maturation. SCN can be diagnosed by identifying the follicular nucleus (Dale 2017). SCN usually begins between the ages of 6 and 8 years. While AML is diagnosed before the age of 1 month, the diagnosis of CyN is generally made during the first 2 years of life or later. The main clinical finding is recurrent acute oral medical illness. When SCN is suspected, malignant hematologic disorders to exclude other diseases, determine cellularity, assess bone marrow maturity, and detect signs of precise etiology. Therefore, bone marrow examination is often required, with cytogenetic bone marrow testing now being definitive. When assessing SCN and CyN, antineutrophil antibody assay, immunoglobulin assay (Ig GAM), lymphocyte immunophenotyping, pancreatic markers (serum trypsinogen and fecal enzyme Calcium phosphate) and fat-soluble vitamin levels (vitamins A, E, and D) are also of concern ( See Donadieu 2011).

[0009] SCN is an autosomal recessive (HAX1, G6PC3) and autosomal dominant (E It can be inherited in the form of an X-linked (WAS) or sporadic It can also occur sexually (Carlsson et al. 2012; Boxer 2012).

[0010] Cyclic and congenital neutropenia are caused by a gene mutation in the neutrophil elastase gene (ELANE gene). )—most often caused by mutations in the gene for neutrophil elastase ELANE gene mutations are identified in 40-55% of SCN patients, equally in men and women. The onset of the disease is rapid (Donadieu et al., 2011; Dale 2017). Mutations in this gene have been associated with autosomal and sporadic cases of SCN (Carlsson To date, over 200 different ELANE mutations have been identified. Randomly distributed across all exons and introns 3 and 4 For example, C, which is particularly associated with poor prognosis, Over 120 distinct CyN- and SCN-related mutations, such as 151Y and G214R ELANE gene mutations are now known (ELANE genes associated with CyN and SCN). For a comprehensive list of genes, see Makaryan et al., 2012; also see Germe see shausen et al., 2013 ).

[0011] ELANE is a neutrophil extracellular trap (a network of fibers that binds to pathogens) It encodes neutrophil elastase (NE), which is involved in the It has been suggested that NE products interfere with the production of neutrophils in the bone marrow, causing neutropenia. These studies have shown that mutations in NE induce the unfolded protein response (UPR). This leads to cell loss in the neutrophil formation process in the bone marrow (Maka ryan et al., 2017).

[0012] Current treatment Granulocyte colony-stimulating factor (G-CSF) is considered the first-line treatment for SCN (Co (Nnelly, Choi, and Levine 2012). G-CSF induces more neutrophils. stimulates the production of ATP and delays apoptosis (Schaffer and Klein 200 7) Although 10% of SCN patients still die from severe bacterial infection or sepsis, Overall survival, including patients with developing genital lesions, is now estimated to be over 80%. (Skokowa et al., 2017). G-CSF therapy has been shown to prevent deaths from sepsis. Although successful, long-term treatment can lead to myelodysplastic syndrome (MDS) or alopecia in SCN patients. It has been shown that this is associated with an increased risk of developing hematologic diseases. The most common leukemia is AML, but there are also acute lymphoblastic leukemia (ALL), juvenile myelomonocytic leukemia (JMLL), and leukemia-associated leukemia (LA). JMML, chronic myelomonocytic leukemia (CMML), and biphenotypic leukemia are also included in the literature. (Connelly, Choi, and Levine 2012). Patients who showed a strong response to CSF ​​(dose less than 8 μg / kg / day) were treated with G-CSF. The cumulative incidence of MDS / leukemia after 15 years was 15%, regardless of the high dose. However, it has been previously reported that the incidence of poor response to G-CSF was 34%. was reported (Rosenberg et al., 2010).

[0013] Hematopoietic stem cell transplantation (HSCT) is recommended for patients who do not respond to G-CSF therapy or who develop AML / MDS. However, chronic neutrophils undergoing HCT are still at increased risk of developing neutrophil deficiency. Cytopenic patients are at increased risk of developing infectious complications, including fungal and graft-versus-host disease (Skokowa et al., 2017). Furthermore, in HCT, adaptation is required to improve survival. A related donor is required, but most patients do not have a matched donor available (Con nelly, Choi, and Levine 2012). Summary of the Invention

[0014] Disclosed are methods for disrupting dominant mutant alleles or degrading the resulting mRNA. This technique knocks out the expression of a dominant mutant allele by inducing a knockout gene.

[0015] The present disclosure provides a method for identifying a gene encoding a mutant protein in which one allele encodes a mutant protein whose mutation results in a disease phenotype. One allele carries a mutation (the "mutated allele"), while the other allele encodes a functional protein. to distinguish between two alleles of a gene ("functional alleles"). at least one naturally occurring heterozygous nucleotide difference or genetic polymorphism (single nucleotide polymorphism) We provide a method for utilizing SNPs (e.g., SNPs)

[0016] Embodiments of the present invention involve the identification of dominant mutant alleles in a given cell or subject. The present invention provides a method that utilizes at least one heterozygous SNP in an expressed gene. In certain embodiments, the SNPs utilized may or may not be associated with a disease phenotype. In an embodiment of the invention, an RNA molecule comprising a guide sequence is heterozygous SNPs, and therefore different nucleotides in the functional alleles of the gene. Targeting nucleotide bases with nucleotide bases to identify mutant alleles of genes To target.

[0017] In some embodiments, the method knocks out expression of a mutant protein and inhibits its function. The method further comprises the step of allowing expression of the functional protein.

[0018] The present invention relates to the treatment of severe congenital neutropenia (SCN) or cyclic neutropenia (Cy Neutrophil elastase gene (ELANE gene) with mutations associated with N a method for inactivating a mutant allele of rs104l4837, rs376l005, rs1683564, rs9749274, rs74002l, r s20l048029, rs199720952, rs28591229, rs7l33 5276, rs58082l77, rs3826946, rs10413889, rs7 6l48l944, rs376l008, rs10409474, rs3761007, rs172l6649, rs10469327, rs8l07095, rs104244 rs70 and rs78302854. The method is To the cells, a CRISPR nuclease or a sequence encoding a CRISPR nuclease, and A composition comprising a first RNA molecule containing a guide sequence portion having 17 to 20 nucleotides. introducing a composition into the The complex of CRISPR nuclease and the first RNA molecule encodes a mutation in the ELANE gene. A method is provided for affecting double-strand breaks in alleles.

[0019] The present invention provides modified cells obtained by the methods of the present invention.

[0020] The present invention provides modified cells lacking at least a portion of one allele of the ELANE gene. Provide cells.

[0021] The present invention provides compositions comprising modified cells and a pharmaceutically acceptable carrier.

[0022] The present invention also provides a method for producing a composition comprising mixing the cells of the present invention with a pharmaceutically acceptable carrier. In vitro or ex vivo preparation methods are provided.

[0023] The present invention provides a method for preparing a composition comprising modified cells in vitro or ex vivo. , the method is a) ELANE gene mutations associated with SCN or CyN and / or SCN or isolating HSPCs from cells obtained from a subject suffering from CyN, wherein the subject , rs104l4837, rs376l005, rs1683564, rs974927 4, rs740021, rs201048029, rs199720952, rs285 91229, rs7l335276, rs58082l77, rs3826946, rs 104l3889, rs76148l944, rs376l008, rs1040947 4, rs3761007, rs17216649, rs10469327, rs8l07 095, rs10424470, and rs78302854 or heterozygous at multiple polymorphic sites, isolating and obtaining cells from the subject. thing, b) inactivating a mutant allele of the ELANE gene in one or more cells; In the cells of step (a), a CRISPR nuclease or a sequence encoding a CRISPR nuclease, and a first RNA molecule comprising a guide sequence portion having 17 to 20 nucleotides; introducing a composition, The complex of the CRISPR nuclease and the first RNA molecule is expressed in one or more cells. affecting double-strand breaks in mutant alleles of the ELANE gene in Optionally, the cell is provided with a guide capable of forming a complex with a CRISPR nuclease. and introducing a second RNA molecule comprising a CRI. The SPR nuclease complex binds to one or more ELANE genes in the cells. affecting the second double-strand break, thereby obtaining, introducing, and optionally c) culturing and growing the modified cells of step (b), wherein the modified cells engraft; and culturing the resulting cells to produce progeny cells after engraftment. Provide.

[0024] The present invention provides a) ELANE gene mutations associated with SCN or CyN and / or SCN or isolating HSPCs from cells obtained from a subject suffering from CyN, wherein the subject , rs104l4837, rs376l005, rs1683564, rs974927 4, rs740021, rs201048029, rs199720952, rs285 91229, rs7l335276, rs58082l77, rs3826946, rs 104l3889, rs76148l944, rs376l008, rs1040947 4, rs3761007, rs17216649, rs10469327, rs8l07 095, rs10424470, and rs78302854 or heterozygous at multiple polymorphic sites, b) inactivating a mutant allele of the ELANE gene in one or more cells; In the cells of step (a), a CRISPR nuclease or a sequence encoding a CRISPR nuclease, and a first RNA molecule comprising a guide sequence portion having 17 to 20 nucleotides; introducing a composition, The complex of the CRISPR nuclease and the first RNA molecule is expressed in one or more cells. affecting double-strand breaks in mutant alleles of the ELANE gene in Optionally, the cell is provided with a guide capable of forming a complex with a CRISPR nuclease. and introducing a second RNA molecule comprising a CRI. The SPR nuclease complex binds to a second ELANE gene in one or more cells. Affects double-strand breaks, thereby obtaining, introducing, and optionally c) culturing and expanding the cells of step (b), wherein the modified cells are capable of engraftment. and culturing the cells to give rise to progeny cells after engraftment; d) administering step (b) or step (c) to a subject to treat SCN or CyN in the subject. and administering to the subject a cell of the present invention a method for the preparation of a composition of matter comprising administering to the subject a cell of the present invention a cell of the present invention. Provide.

[0025] The present invention provides a therapeutically effective amount of the modified cells, compositions, or compositions prepared by the methods of the present invention. The present invention provides a method for treating a subject suffering from SCN or CyN, comprising administering

[0026] The present invention relates to a method for treating patients with ELANE gene mutations associated with SCN or CyN. A method for treating SCN or CyN in a subject, the subject having rs104l483 7, rs376l005, rs1683564, rs9749274, rs74002l , rs20l048029, rs199720952, rs2859l229, rs7l 335276, rs58082177, rs3826946, rs104l3889, r s76l481944, rs376l008, rs10409474, rs376100 7, rs172l6649, rs10469327, rs8l07095, rs1042 4470 and rs78302854 heterozygous, and the method comprises: a) isolating HSPCs from cells obtained from a subject; b) inactivating a mutant allele of the ELANE gene in one or more cells; In the cells of step (a), a CRISPR nuclease or a sequence encoding a CRISPR nuclease, and a first RNA molecule comprising a guide sequence portion having 17 to 20 nucleotides; introducing a composition, The complex of the CRISPR nuclease and the first RNA molecule is expressed in one or more cells. affecting double-strand breaks in mutant alleles of the ELANE gene in Optionally, the cell is provided with a guide capable of forming a complex with a CRISPR nuclease. and introducing a second RNA molecule comprising a CRI. The SPR nuclease complex binds to a second ELANE gene in one or more cells. Affects double-strand breaks, thereby obtaining, introducing, and optionally c) culturing and expanding the cells of step (b), wherein the modified cells are capable of engraftment. and culturing the cells to give rise to progeny cells after engraftment; d) administering to the subject the cells of step (b) or step (c), thereby generating SCs in the subject. The present invention provides a method for treating N or CyN.

[0027] The present invention relates to a method for treating patients with ELANE gene mutations associated with SCN or CyN. A method for treating SCN or CyN in a subject, the subject having rs1041483 7, rs3761005, rs1683564, rs9749274, rs740021 , rs201048029, rs199720952, rs28591229, rs71 335276, rs58082177, rs3826946, rs10413889, r s761481944, rs3761008, rs10409474, rs376100 7, rs17216649, rs10469327, rs8107095, rs1042 4470 and rs78302854 heterozygous, and the method comprises: administering to the subject autologous modified cells or progeny of the autologous modified cells, wherein the autologous modified cells , the mutant allele of the ELANE gene is modified to produce a double-strand break; The double-strand break is generated by a CRISPR nuclease or a CRISPR nuclease-coating. a composition comprising a CRIS encoding sequence and a first RNA molecule into a cell, The complex of PR nuclease and the first RNA molecule induces mutations in the ELANE gene in cells. The mutant allele of the ELANE gene generates a double-strand break, inactivating the other allele. affecting, administering, Thereby, methods are provided for treating SCN or CyN in a subject.

[0028] The present invention provides a method for selecting subjects for treatment from a pool of subjects diagnosed with SCN or CyN. The method comprises: a) obtaining cells from each subject in a pool of subjects; b) Cells from each subject were screened for ELANE gene mutations associated with SCN or CyN. a step of selecting only subjects with ELANE gene mutations associated with SCN or CyN; P, c) sequencing the cells of the subjects selected in step (b) to identify rs10 4l4837, rs376l005, rs1683564 or selecting for heterozygosity at a plurality of polymorphic sites; and d) Only subjects with cells heterozygous at one or more polymorphic sites for treatment selecting a

[0029] An embodiment of the present invention comprises: e) From the subject's bone marrow, either by aspiration of peripheral blood or by mobilization and apheresis. to obtain hematopoietic stem and progenitor cells (HSPCs) by f) HSPC cells from step (e) one or more CRISPR nucleases or one or more CRISPR nucleases ase-encoding sequence Heterozygous junction of one or more polymorphic sites present in the mutant allele of the ELANE gene Any one of SEQ ID NOs: 1 to 1192 targeting the nucleotide base of the synthetic allele 17-20 nucleotides in a sequence of 17-20 adjacent nucleotides described a first RNA molecule comprising a guide sequence portion having a nucleic acid sequence; and Targeting sequences in intron 3, intron 4, or 3'UTR of the ELANE gene and introducing a second RNA molecule comprising a targeted guide sequence portion, The complex of the first RNA molecule and the CRISPR nuclease is then transduced into one or more HSPCs. The first affects a double-strand break in the mutant allele of the ELANE gene in cells, and the second affects a double-strand break in the mutant allele of the ELANE gene in cells. The complex of the RNA molecule and CRISPR nuclease binds the first RNA molecule and the CRISPR nuclease. The cleavage complex affects one or more HSPC cells to make the first double-strand break. Intron 3, intron 4, or 3'UTR of both alleles of the ELANE gene in introducing the modified gene into the target cell, thereby affecting a second double-strand break, thereby obtaining a modified cell; g) administering to the subject the modified cells of step (f), thereby enhancing the SCN or CyN of the subject. and further treating SCN or CyN in a selected subject, including treating Included.

[0030] The present invention relates to a method for producing a nucleic acid sequence comprising the steps of: The guide sequence portion has 17 to 20 nucleotides in the sequence of nucleotides The present invention provides an RNA molecule containing the

[0031] The present invention provides a method for inactivating a mutant ELANE allele in a cell, the method comprising: Methods are provided that include delivering an RNA molecule or composition of the invention to a cell.

[0032] The present invention relates to a method for inactivating a mutant ELANE allele in a cell using an RNA of the present invention. Uses of the molecules, compositions of the invention or compositions prepared by the methods of the invention are provided.

[0033] The present invention provides a method for the inactivation of a mutant ELANE allele in a cell, comprising administering to said cell a therapeutic agent of the present invention. a drug comprising an RNA molecule, a composition of the present invention, or a composition prepared by a method of the present invention. and injecting the RNA molecule of the present invention, the composition of the present invention, or the composition prepared by the method of the present invention into the cell. Administering a drug by delivering an object, providing a drug.

[0034] The present invention provides a method for treating SCN or CyN in a subject having or at risk of having SCN or CyN. The methods of the invention, the modified cells of the invention, the compositions of the invention for treating, ameliorating, or preventing CyN The present invention provides a method for producing a composition of matter comprising the steps of: do.

[0035] The present invention provides an RNA of the present invention for use in treating, ameliorating or preventing SCN or CyN. a molecule of the invention, a composition of the invention, a composition prepared by a method of the invention, or a modified cell of the invention. and administering the R of the present invention to a subject having or at risk of having SCN or CyN. NA molecule, composition of the present invention, composition prepared by the method of the present invention, or modified cell of the present invention The drug is administered by delivering the drug.

[0036] The present invention relates to an RNA molecule, a CRISPR nuclease or a CRISPR nuclease of the present invention. a sequence encoding a tracrRNA molecule or a sequence encoding a tracrRNA molecule; and RNA molecules to inactivate the mutant ELANE allele in cells. , a CRISPR nuclease or a sequence encoding a CRISPR nuclease, and / or for delivering tracrRNA or a sequence encoding a tracrRNA molecule to cells. A kit for inactivating a mutant ELANE allele in a cell, comprising instructions for use in the kit. do.

[0037] The present invention relates to an RNA molecule, a CRISPR nuclease or a CRISPR nuclease of the present invention. a sequence encoding a tracrRNA molecule or a sequence encoding a tracrRNA molecule; The CRISPR nucleases are designed to treat SCN or CyN. Patients with or at risk of having SCN or CyN and a kit for treating SCN or CyN in a subject, the kit comprising instructions for delivering the kit to an elephant. provide.

[0038] The present invention relates to a composition of the present invention, a composition prepared by a method of the present invention, or a modification of the present invention. Cells and methods for delivering compositions to cells to inactivate the ELANE gene in the cells and a kit for inactivating a mutant ELANE allele in a cell, the kit comprising: .

[0039] The present invention relates to a composition of the present invention, a composition prepared by a method of the present invention, or a modification of the present invention. Cells, and compositions of the present invention for treating SCN or CyN, prepared by the methods of the present invention The compositions or modified cells of the invention may have or be at risk of having SCN or CyN. A kit for treating SCN or CyN in a subject, comprising instructions for delivery to the subject. to provide. [Brief explanation of the drawings]

[0040] [Figure 1] Figure 1. Excising the promoter region from upstream of the SNP position to intron 3, intron 4 or the 3'UTR. In one example, the first guide sequence targets a specific sequence at the heterozygous SNP position in the upstream region of the mutant allele (strategy la-rs104l4837, strategy lb-rs376l005), and the second guide sequence targets a sequence in intron 4 that is common to the two alleles of the gene. [Figure 2] Figure 2. Excision of the promoter region from upstream of the SNP position to intron 3, intron 4, or the 3'UTR. In one example, the first guide sequence targets a specific sequence at the heterozygous SNP position in the upstream region of the mutant allele (strategy la-rs10414837, strategy lb-rs3761005), and the second guide sequence targets a sequence in intron 3 that is common to the two alleles of the gene. In another example, the first guide sequence targets a specific sequence at the heterozygous SNP position in the upstream region of the mutant allele (strategy la-rs10414837, strategy lb-rs3761005), and the second guide sequence targets a sequence in the 3'UTR that is common to the two alleles of the gene. [Figure 3]Figure 3. Excision of intron 3, intron 4, or the 3'UTR to a region downstream of the 3'UTR. In one example, a first guide sequence targets a specific sequence at a heterozygous SNP position in the upstream region of a mutant allele (Strategy 2-rs1683564), and a second guide sequence targets a sequence in intron 4 that is common to the two alleles of the gene. In another example, a first guide sequence targets a specific sequence at a heterozygous SNP position in the upstream region of a mutant allele (Strategy 2-rs1683564), and a second guide sequence targets a sequence in intron 3 that is common to the two alleles of the gene. In a further example, a first guide sequence targets a specific sequence at a heterozygous SNP position in the upstream region of a mutant allele (Strategy 2-rs1683564), and a second guide sequence targets a sequence in the 3'UTR that is common to the two alleles of the gene. [Figure 4] Figure 4. Excision of intron 3, intron 4, or the 3'UTR to a region downstream of the 3'UTR. This strategy is designed to specifically knock out disease-causing alleles ("mutant alleles") while leaving healthy alleles intact. Allele-specific editing is achieved by using guides that target discriminating (heterozygous) SNP positions with relatively high heterozygous frequency in the population. [Figure 5] Figure 5. Expected coverage within a population based on heterozygosity frequency and overlap / linkage between selected heterozygous SNPs. Designing alternative solutions for the three treatment strategies may result in inclusion of approximately 80% of the population. Approximately 80% of the population is assessed as carrying one or more heterozygous SNPs from the list above. Of these, 33% carry one heterozygous SNP, 31% carry two heterozygous SNPs from the list, and 16% carry three heterozygous SNPs, while 20% do not carry any SNPs from the list above. [Figure 6]Figure 6. HeLa cells were seeded in 96-well plates (3K / well). After 24 hours, they were co-transfected with 65 ng of WT-Cas9 or Dead-Cas9 and 20 ng of gRNA plasmids, identified as g36 to g66 and targeting different regions and SNPs in ELANE, using Turbofect reagent (Thermo Scientific). Percent editing was calculated according to the following formula: 100% - (unedited band intensity / total band intensity) x 100. The average activity of each gRNA ± SD after subtracting the Dead-Cas9 background activity from three independent experiments is shown. [Figure 7] Figure 7. HSCs from healthy donors were nucleofected with spCas9-WT and the RNA components of gRNAs targeting either EMX1 (sgEMXl) or ELANE (g35:INT4; g58:rs376l005; g62:rs1683564). Seventy-two hours post-nucleofection, gDNA was extracted and editing levels were quantified by IDAA. Mean % editing ± SD of two independent experiments performed in duplicate is shown. [Figure 8] Figure 8. Specific knockout of a mutant allele of the ELANE gene is mediated by excising intron 4 and exon 5 of the mutant allele of the ELANE gene. This is achieved by mediating a DSB in intron 4 and utilizing SNP rs1683564 to mediate an allele-specific DSB. DETAILED DESCRIPTION OF THE INVENTION

[0041] An embodiment of the present invention is directed to the treatment of cells with severe congenital neutropenia (SCN) or cyclic neutropenia. Neutrophil elastase gene (ELANE gene) with mutations associated with CyN syndrome (CyN) A method for inactivating a mutant allele of a gene, comprising: 4837, rs376l005, rs1683564, rs9749274, rs740 02l, rs20l048029, rs199720952, rs28591229, r s7l335276, rs58082l77, rs3826946, rs1041388 9, rs76l48l944, rs376l008, rs10409474, rs376 1007, rs172l6649, rs10469327, rs8l07095, rs1 One or more polymorphisms selected from the group consisting of rs78302854 and rs78304470 heterozygous at the site, and the method comprises: To the cells, a CRISPR nuclease or a sequence encoding a CRISPR nuclease, and A composition comprising a first RNA molecule containing a guide sequence portion having 17 to 20 nucleotides. introducing a composition into the The complex of CRISPR nuclease and the first RNA molecule encodes a mutation in the ELANE gene. A method is provided for affecting double-strand breaks in alleles.

[0042] In an embodiment of the invention, the CRISPR nuclease and the first RNA molecule are Affects double-strand breaks in mutant alleles of the ANE gene, and mutant alleles Targeting for double-strand breaks based on multiple polymorphic sites.

[0043] In an embodiment of the invention, the CRISPR nuclease and the first RNA molecule are Affects double-strand breaks in mutant alleles of the ANE gene, and mutant alleles Targeting for double-strand breaks based on the sequence of the mutant allele at multiple polymorphic sites.

[0044] In an embodiment of the invention, the CRISPR nuclease and the first RNA molecule are The nucleotide bases at one or more polymorphic sites present in the mutant alleles of the ANE gene Based on the effect on double-strand breaks in mutant alleles of the ELANE gene.

[0045] Embodiments of the present invention provide guides capable of forming complexes with CRISPR nucleases. and introducing a second RNA molecule comprising a C-terminal sequence portion, The RISPR nuclease complex affects a second double-strand break in the ELANE gene. do.

[0046] In an embodiment of the invention, the composition comprises one, two, three or more CRISPR nuclei. In some embodiments of the present invention, the nucleic acid may comprise a sequence encoding a CRISPR nuclease or a CRISPR nuclease. In the method, introducing a composition into a cell includes introducing one, two, three, or more compositions into a cell. In an embodiment of the invention, each composition comprises a different CRISPR nuclease. or a sequence encoding a CRISPR nuclease or an identical CRISPR nuclease The two RNA molecules may contain sequences encoding a CRISPR nuclease or a CRISPR nuclease. In embodiments of the invention comprising a second RNA molecule, the second RNA molecule has the same CR sequence as the first RNA molecule. It may be complexed with an ISPR nuclease or with another CRISPR nuclease. A coalescence may be formed.

[0047] In an embodiment of the invention, the second double-strand break is located within a non-coding region of the ELANE gene. In an embodiment of the present invention, the non-coding region of the ELANE gene is an intron or is selected from the untranslated region (UTR). In an embodiment of the invention, the non-coding region is In an embodiment of the invention, the UTR is intron 3 or intron 4. It's R.

[0048] In an embodiment of the present invention, the guide sequence portion of the first RNA molecule is selected from the group consisting of SEQ ID NOs: 1 to 11. 92.

[0049] According to an embodiment of the present invention, the guide sequence portion of the second RNA molecule is selected from the group consisting of SEQ ID NOs: 1 to 11. 92 or any one of SEQ ID NOs: 1193 to 2000 It contains 17-20 nucleotides in a sequence of ~20 contiguous nucleotides.

[0050] In an embodiment of the invention, the second double-strand break is located within a non-coding region of the ELANE gene. is

[0051] In an embodiment of the invention, the cells are Heterozygous, the complex of the second RNA molecule and the CRISPR nuclease is Affects double-strand breaks in intron 4 of the ANE gene.

[0052] In an embodiment of the invention, the cells are Heterozygous, the complex of the second RNA molecule and the CRISPR nuclease is Affects double-strand breaks in intron 3 of the ANE gene.

[0053] In an embodiment of the invention, the cells are Heterozygous, the complex of the second RNA molecule and the CRISPR nuclease is Affecting double-strand breaks in the 3'UTR region of the ANE gene.

[0054] In an embodiment of the invention, the cells are heterozygous at rs1683564 and The RNA molecule and CRISPR nuclease complex are inserted into an intron of the ELANE gene. Affects double-strand breaks at 4.

[0055] In an embodiment of the invention, the cells are heterozygous at rs1683564 and The RNA molecule and CRISPR nuclease complex are inserted into an intron of the ELANE gene. 3 affects the double-strand break.

[0056] In an embodiment of the invention, the cells are heterozygous at rs1683564 and The RNA molecule and CRISPR nuclease complex binds to the 3'UTR of the ELANE gene. Affects double-strand breaks in the region.

[0057] In some embodiments, the cells contain the ELANE rs10414837 polymorphism. a first gene containing a guide sequence portion having 17 to 20 nucleotides and heterozygous at position The complex of the RNA molecule and CRISPR nuclease binds to the mutant allele of the ELANE gene. Affects double-strand breaks in genes and double-strand breaks in functional alleles of the ELANE gene In such an embodiment, the guide sequence portion of the first RNA molecule is SEQ ID NO: 82, 86, 93, 94, 115, having 17 to 20 nucleotides. , 119, 135, 173, 180, 213, 215, 224, 225, 262, 263 , 307, 308, 319, 323, 351, 352, 374, 461, 462, 466 , 467, 474, 477, 478, 491, 504, 505, 533, 537, 538 , 550, 556, 569, 570, 583, 584, 684, 685, 714, 745 , 790, 791, 845, 846, 854, 857, 858, 861, 863, 864 , 880, 881, 886, 890, 891, 901, 911, 912, 936, 937 , 939, 940, 960, 961, 972, 978, 979, 983, 984, 101 8, 1034, 1035, 1040, 1086, 1110, 1111, 1135, 114 17 to 20 adjacent nucleotides described in either 4 or 1145 may include an array of:

[0058] In some embodiments, the cells contain a polymorphic site at ELANE rs376l005. a first sequence containing a guide sequence portion having 17 to 20 nucleotides; The complex between the RNA molecule and the CRISPR nuclease encodes a mutant allele of the ELANE gene. affecting double-strand breaks in offspring and double-strand breaks in functional alleles of the ELANE gene In such an embodiment, the guide sequence portion of the first RNA molecule is 17 having up to 20 nucleotides and comprising SEQ ID NOs: 26, 57, 65, 66, 70, 18 7, 188, 191, 206, 220, 221, 243, 245, 261, 275, 35 6, 357, 392, 417, 418, 431, 441, 442, 447, 488, 51 3, 514, 545, 546, 548, 598, 599, 604, 607, 608, 61 2, 613, 639, 648, 658, 659, 660, 680, 681, 742, 74 3, 755, 756, 759, 762, 763, 767, 771, 772, 773, 78 6, 787, 815, 816, 818, 819, 820, 831, 836, 849, 85 0, 870, 871, 898, 899, 907, 908, 1009, 1010, 1013 , 1023, 1029, 1030, 1082, 1083, 4093, 1099, 1100 17 to 20 described in any one of 1101, 1107, 1108 and 1182 It may comprise a sequence of nucleotides of adjacent nucleotides.

[0059] In some embodiments, the cells contain a polymorphic site at ELANE rs1683564. a first sequence containing a guide sequence portion having 17 to 20 nucleotides; The complex between the RNA molecule and the CRISPR nuclease encodes a mutant allele of the ELANE gene. affecting double-strand breaks in offspring and double-strand breaks in functional alleles of the ELANE gene In such an embodiment, the guide sequence portion of the first RNA molecule is 17 having 20 nucleotides or less, and comprising SEQ ID NOs: 52, 87, 122, 164, 175 , 199, 214, 290, 326, 345, 346, 373, 404, 412, 436 , 437, 451, 452, 483, 484, 517, 520, 525, 617, 618 , 621, 641, 661, 676, 722, 736, 806, 855, 856, 878 , 879, 888, 889, 896, 903, 905, 913, 914, 929, 933 , 934, 935, 982, 998, 1021, 1022, 1026, 1046, 104 7, 1053, 1097, 1121, 1122, 1124, 1126, 1127, 113 1, 1134, 1175, 1176, 1183 and 1190 It may comprise a sequence of 17 to 20 adjacent nucleotides.

[0060] Embodiments of the present invention relate to severe congenital neutropenia (SCN) or CyN-associated E Cells with LANE gene mutations were analyzed by immunofluorescence microscopy using the ELANE gene associated with SCN or CyN. and obtaining the subject from a subject having a mutation and / or suffering from SCN or CyN, , rs10414837, rs3761005, rs1683564, rs974927 4, rs740021, rs201048029, rs199720952, rs285 91229, rs71335276, rs58082177, rs3826946, rs 10413889, rs761481944, rs3761008, rs1040947 4, rs3761007, rs17216649, rs10469327, rs8107 095, rs10424470, and rs78302854 or heterozygous at multiple polymorphic sites.

[0061] An embodiment of the present invention is directed to detecting ELANE gene mutations associated with SCN or CyN. Selecting a subject having and / or suffering from SCN or CyN, the subject being 10414837, rs3761005, rs1683564, rs9749274, r s740021, rs201048029, rs199720952, rs285912 29, rs71335276, rs58082177, rs3826946, rs104 13889, rs761481944, rs376l008, rs10409474, r s376l007, rs172l6649, rs10469327, rs8107095 rs10424470 and rs78302854 The method includes obtaining cells from a subject who is heterozygous at a number of polymorphic sites.

[0062] Embodiments of the present invention involve the removal of cells from a subject by mobilization and / or apheresis. This includes gaining something.

[0063] An embodiment of the invention involves obtaining cells from a subject by bone marrow aspirate.

[0064] In an embodiment of the invention, the cells are primed before the composition is introduced into the cells.

[0065] An embodiment of the present invention involves growing cells in culture to obtain a cell population.

[0066] In an embodiment of the invention, the cells are treated with stem cell factor (SCF), IL-3 and GM-CS. The cells are cultured with one or more of F.

[0067] In an embodiment of the invention, the cells are cultured with at least one cytokine.

[0068] In an embodiment of the invention, the at least one cytokine is a recombinant human cytokine. It is.

[0069] In an embodiment of the invention, the cell is one of a plurality of cells and contains a first RNA molecule or a composition comprising both the first and second RNA molecules, and other cells, and ELA in at least the cells among the plurality of cells and the other cells. The mutant allele of the NE gene is inactivated, thereby obtaining a plurality of modified cells.

[0070] In an embodiment of the invention, a composition comprising a first RNA molecule or a second RNA molecule is introduced. The introduction of the RNA molecule comprises electroporation of the cell or cells.

[0071] An embodiment of the present invention provides modified cells obtained by the methods of the present invention.

[0072] In an embodiment of the invention, the modified cells are further propagated in culture.

[0073] In an embodiment of the invention, the modified cells are capable of engrafting.

[0074] In an embodiment of the invention, the modified cells are capable of long-term engraftment when injected into a patient; At least 12 months after injection, preferably at least 24 months, and even more preferably Preferably, the cells give rise to differentiated hematopoietic cells for at least 30 months after injection. In this case, the modified cells are capable of long-term engraftment when injected into an autologous subject. In this method, the modified cells can be injected into a subject without myeloablation and remain engrafted for a long period of time. In an embodiment of the invention, the modified cells provide long-term engraftment upon engraftment in a human subject. The antibodies are delivered to the subject in sufficient numbers to

[0075] In an embodiment of the invention, the modified cell or cells are capable of giving rise to progeny cells. do.

[0076] In an embodiment of the invention, the modified cell or cells give rise to progeny cells after engraftment. This can be done.

[0077] In an embodiment of the invention, the modified cell or cells give rise to progeny cells after autologous transplantation. It is possible.

[0078] In an embodiment of the invention, the modified cells or modified cells are maintained for at least 12 months after engraftment. or capable of giving rise to progeny cells for at least 24 months.

[0079] In one embodiment, the cell or cells are stem cells. In one embodiment, the cells are embryonic stem cells. In one embodiment, the stem cells are hematopoietic stem / progenitor cells. These cells are called HSPCs.

[0080] In an embodiment of the invention, the modified cell or cells are CD34+ hematopoietic stem cells. .

[0081] In an embodiment of the present invention, the modified cells or modified cell population are bone marrow cells or peripheral mononuclear cells ( PMC).

[0082] An embodiment of the present invention is a method for producing a mouse model lacking at least a portion of one allele of the ELANE gene. The present invention provides modified cells comprising:

[0083] In an embodiment of the present invention, the modified cells contain rs104l4837, rs3761005 , rs1683564, rs9749274, rs74002l, rs20l04802 9, rs199720952, rs2859l229, rs7l335276, rs58 082l77, rs3826946, rs104l3889, rs76l48l944, rs376l008, rs10409474, rs376l007, rs172l664 9, rs10469327, rs8107095, rs10424470 and rs783 02854. Modified from.

[0084] Embodiments of the present invention provide compositions comprising modified cells and a pharmaceutically acceptable carrier.

[0085] An embodiment of the invention includes combining the cells of the invention with a pharmaceutically acceptable carrier. In particular, methods for preparing the compositions in vitro or ex vivo are provided.

[0086] Embodiments of the present invention include methods for preparing compositions comprising modified cells in vitro or ex vivo. A method, the method being: a) ELANE gene mutations associated with SCN or CyN and / or SCN or isolating HSPCs from a plurality of cells obtained from a subject suffering from CyN, The targets are rs104l4837, rs376l005, rs1683564, and rs974 9274, rs740021, rs201048029, rs199720952, rs 28591229, rs7l335276, rs58082l77, rs3826946 , rs104l3889, rs76148l944, rs376l008, rs1040 9474, rs3761007, rs17216649, rs10469327, rs8 l07095, rs10424470 and rs78302854 and isolating and removing cells from a subject that are heterozygous at one or more polymorphic sites. To gain, b) inactivating a mutant allele of the ELANE gene in one or more cells; In the cells of step (a), a CRISPR nuclease or a sequence encoding a CRISPR nuclease, and a first RNA molecule comprising a guide sequence portion having 17 to 20 nucleotides; introducing a composition, The complex of the CRISPR nuclease and the first RNA molecule is expressed in one or more cells. affecting double-strand breaks in mutant alleles of the ELANE gene in Optionally, a guide capable of forming a complex with a CRISPR nuclease in a cell. introducing a second RNA molecule comprising a sequence portion, wherein the second RNA molecule and the CRIS The PR nuclease complex binds to the first gene in the ELANE gene in one or more cells. and optionally introducing a double-stranded break into the target gene, thereby obtaining a modified cell. c) culturing and growing the modified cells of step (b), wherein the modified cells engraft; and culturing the resulting cells to produce progeny cells after engraftment. To provide.

[0087] An embodiment of the present invention comprises: a) ELANE gene mutations associated with SCN or CyN and / or SCN or isolating HSPCs from cells obtained from a subject suffering from CyN, wherein the subject , rs104l4837, rs376l005, rs1683564, rs974927 4, rs740021, rs201048029, rs199720952, rs285 91229, rs7l335276, rs58082l77, rs3826946, rs 104l3889, rs76148l944, rs376l008, rs1040947 4, rs3761007, rs17216649, rs10469327, rs8l07 095, rs10424470, and rs78302854 or heterozygous at multiple polymorphic sites, b) inactivating a mutant allele of the ELANE gene in one or more cells; In the cells of step (a), a CRISPR nuclease or a sequence encoding a CRISPR nuclease, and a first RNA molecule comprising a guide sequence portion having 17 to 20 nucleotides; introducing a composition, The complex of the CRISPR nuclease and the first RNA molecule is expressed in one or more cells. affecting double-strand breaks in mutant alleles of the ELANE gene in Optionally, the cell is provided with a guide capable of forming a complex with a CRISPR nuclease. and introducing a second RNA molecule comprising a CRI. The SPR nuclease complex binds to one or more ELANE genes in the cells. affecting the second double-strand break, thereby obtaining, introducing, and optionally c) culturing and expanding the cells of step (b), wherein the modified cells are capable of engraftment. and culturing the cells to give rise to progeny cells after engraftment; d) administering step (b) or step (c) to a subject to treat SCN or CyN in the subject. and administering to the subject a cell of the present invention a method for the preparation of a composition of matter comprising administering to the subject a cell of the present invention a cell of the present invention. To provide.

[0088] Embodiments of the present invention include a therapeutically effective amount of a modified cell, composition, or method of the present invention. The present invention provides a method for treating a subject suffering from SCN or CyN, comprising administering a composition containing the compound. To provide.

[0089] An embodiment of the present invention provides a therapeutic agent for treating patients with ELANE gene mutations associated with SCN or CyN. A method for treating SCN or CyN in a subject in need thereof, the subject having rs104 l4837, rs376l005, rs1683564, rs9749274, rs74 002l, rs20l048029, rs199720952, rs2859l229, rs7l335276, rs58082177, rs3826946, rs104l38 89, rs76l481944, rs376l008, rs10409474, rs37 61007, rs172l6649, rs10469327, rs8l07095, rs rs78302854 and rs78302854. heterozygous at the type site, and the method comprises: a) isolating HSPCs from cells obtained from a subject; b) inactivating a mutant allele of the ELANE gene in one or more cells; In the cells of step (a), a CRISPR nuclease or a sequence encoding a CRISPR nuclease, and a first RNA molecule comprising a guide sequence portion having 17 to 20 nucleotides; introducing a composition, The complex of the CRISPR nuclease and the first RNA molecule is expressed in one or more cells. affecting double-strand breaks in mutant alleles of the ELANE gene in Optionally, the cell is provided with a guide capable of forming a complex with a CRISPR nuclease. and introducing a second RNA molecule comprising a CRI. The SPR nuclease complex binds to one or more ELANE genes in the cells. affecting the second double-strand break, thereby obtaining, introducing, and optionally c) culturing and expanding the cells of step (b), wherein the modified cells are capable of engraftment. and culturing the cells to give rise to progeny cells after engraftment; d) administering to the subject the cells of step (b) or step (c), thereby generating SCs in the subject. The present invention provides a method for treating N or CyN.

[0090] An embodiment of the present invention is directed to a method for treating a patient with an ELANE gene mutation associated with SCN or CyN. A method for treating SCN or CyN in a subject in need thereof, the subject receiving rs10 414837, rs3761005, rs1683564, rs9749274, rs7 40021, rs201048029, rs199720952, rs28591229 , rs71335276, rs58082177, rs3826946, rs10413 889, rs761481944, rs3761008, rs10409474, rs3 761007, rs17216649, rs10469327, rs8107095, r one or more selected from the group consisting of s10424470 and rs78302854 heterozygous at the polymorphic site, and the method comprises: administering to a subject autologous modified cells or progeny of the autologous modified cells, is modified so that the mutant allele of the ELANE gene generates a double-strand break, The double-strand break is generated by a CRISPR nuclease or a CRISPR nuclease-coating. and introducing into a cell a composition comprising a CRISPR encoding sequence and a first RNA molecule. The complex of the nuclease and the first RNA molecule detects the mutation of the ELANE gene in the cell. The double-strand break in the mutant allele of the ELANE gene is responsible for inactivating the allele. affecting, including administering, Thereby, methods are provided for treating SCN or CyN in a subject.

[0091] An embodiment of the present invention is directed to selecting a subject for treatment from a pool of subjects diagnosed with SCN or CyN. 1. A method for selecting elephants, the method comprising: a) obtaining cells from each subject in a pool of subjects; b) Cells from each subject were screened for ELANE gene mutations associated with SCN or CyN. a step of selecting only subjects with ELANE gene mutations associated with SCN or CyN; P, c) sequencing the cells of the subjects selected in step (b) to identify rs10 4l4837, rs376l005, rs1683564 or selecting for heterozygosity at a plurality of polymorphic sites; and d) Only subjects with cells heterozygous at one or more polymorphic sites for treatment selecting a

[0092] An embodiment of the present invention comprises: e) From the subject's bone marrow, either by aspiration of peripheral blood or by mobilization and apheresis. To obtain HSPC cells by f) HSPC cells from step (e) one or more CRISPR nucleases or one or more CRISPR nucleases Encoding sequence of enzyme Heterozygosity at one or more polymorphic sites present in mutant alleles of the ELANE gene Any one of SEQ ID NOs: 1 to 1192 targeting the nucleotide base of the sex allele 17-20 nucleotides in a sequence of 17-20 adjacent nucleotides described a first RNA molecule comprising a guide sequence portion having a nucleic acid sequence; and Targeting sequences in intron 3, intron 4 or 3'UTR of the ELANE gene and introducing a second RNA molecule comprising a guide sequence portion of The complex of the first RNA molecule and the CRISPR nuclease binds to one or more HSPC cells. Affects the first double-strand break in the mutant allele of the ELANE gene in the cell and the second The RNA molecule and CRISPR nuclease complex first binds to the RNA molecule and then to the CRISPR nuclease. The R nuclease complex affects one or more HSPCs to make the first double-strand break. Intron 3, intron 4, or 3'U of both alleles of the ELANE gene in cells introducing a second double-strand break in the TR, thereby obtaining modified cells; , g) administering to the subject the modified cells of step (f), thereby enhancing the SCN or CyN of the subject. treating SCN or CyN in a selected subject, comprising treating Further includes:

[0093] An embodiment of the present invention is a method for producing a 17 to 1192 antibody comprising the steps of: A guide having 17 to 20 nucleotides in a sequence of 20 adjacent nucleotides An RNA molecule comprising a nucleotide sequence is provided.

[0094] Embodiments of the invention further include a second RNA molecule that includes a guide sequence portion.

[0095] In an embodiment of the present invention, the second RNA molecule encodes a non-coding region of the ELANE gene. To target.

[0096] In an embodiment of the invention, the nucleotide sequence of the guide sequence portion of the second RNA molecule is The nucleotide sequence is different from the sequence of the guide sequence portion of the first RNA molecule.

[0097] In an embodiment of the invention, the first RNA molecule is a CRISPR nuclease-binding protein. In an embodiment of the invention, the second RNA molecule further comprises a portion having a sequence It further comprises a portion having a sequence that binds to a RISPR nuclease.

[0098] In an embodiment of the invention, the sequence that binds to the CRISPR nuclease is tracr It is an RNA sequence.

[0099] In an embodiment of the invention, the first RNA molecule comprises a portion having a tracr mate sequence. In an embodiment of the invention, the second RNA molecule further comprises a tracr mate sequence. It further includes a moiety having the formula:

[0100] In an embodiment of the invention, the first RNA molecule further comprises one or more linker moieties. In an embodiment of the invention, the second RNA molecule comprises one or more linker moieties. Further includes:

[0101] In an embodiment of the invention, the first RNA molecule is up to 300 nucleotides in length. In an embodiment of the invention, the second RNA molecule is up to 300 nucleotides in length. be.

[0102] In an embodiment of the invention, the composition comprises one or more CRISPR nucleases or Further comprising a sequence encoding one or more CRISPR nucleases. In some embodiments, the composition comprises one or more tracrRNA molecules or one or more tr It further comprises a sequence encoding the acrRNA molecule.

[0103] An embodiment of the present invention provides a method for inactivating a mutant ELANE allele in a cell. The method comprises delivering an RNA molecule or composition of the present invention to a cell. Provide.

[0104] In embodiments of the invention, one or more CRISPR nucleases or one or more a sequence encoding a CRISPR nuclease and an RNA molecule or RNA molecules; , delivered to the subject and / or cells at substantially the same time or at different times.

[0105] In an embodiment of the invention, a tracrRNA molecule or one or more tracrRNAs A sequence encoding the A molecule and an RNA molecule or RNA molecules are administered to a subject and / or a cell. Delivery may be at substantially the same time or at different times.

[0106] In an embodiment of the invention, the method comprises: removing an exon containing a disease-causing mutation from the mutant allele; The A molecule or the first and second RNA molecules flank the entire exon or a portion of the exon. Target the area where

[0107] In an embodiment of the invention, the method comprises the step of extracting the entire open reading frame of a gene, This involves removing a number of exons, or removing the entire gene.

[0108] In an embodiment of the invention, the first RNA molecule or the first and second RNA molecules are Targeting alternative splicing signal sequences between exons and introns of alleles do.

[0109] In an embodiment of the invention, the second RNA molecule comprises a mutant allele and a functional allele. It targets sequences that are present in both

[0110] In an embodiment of the invention, the second RNA molecule targets an intron.

[0111] In an embodiment of the invention, the method comprises: The mutant allele is subjected to insertion or deletion by a frameshift gene. This causes the problem of causing a problem.

[0112] In an embodiment of the invention, the frameshift is inactivation or knockout of the mutant allele. Produces an out.

[0113] In an embodiment of the invention, a frameshift results in a premature stop code in the mutant allele. nonsense mutations resulting in a frameshift in the transcript of the mutant allele The mRNA degradation mechanism occurs.

[0114] In an embodiment of the invention, the inactivation or treatment of the gene encoded by the mutant allele The truncated proteins and functional proteins encoded by the functional alleles are produced. Jiru.

[0115] In an embodiment of the invention, a cell or subject is heterozygous at 005, and a complex of a second RNA molecule and a CRISPR nuclease affects a double-strand break in intron 4 of the ELANE gene.

[0116] In an embodiment of the invention, a cell or subject is heterozygous at 005, and a complex of a second RNA molecule and a CRISPR nuclease affects a double-strand break in intron 3 of the ELANE gene.

[0117] In an embodiment of the invention, a cell or subject is heterozygous at 005, and a complex of a second RNA molecule and a CRISPR nuclease affects double-strand breaks in the 3'UTR region of the ELANE gene.

[0118] In an embodiment of the invention, the cell or subject is heterozygous at rs1683564. The second RNA molecule and the CRISPR nuclease complex then bind to the ELANE gene. Affects double-strand break in intron 4.

[0119] In an embodiment of the invention, the cell or subject is heterozygous at rs1683564. The second RNA molecule and the CRISPR nuclease complex then bind to the ELANE gene. Affects double-strand breaks in intron 3.

[0120] In an embodiment of the invention, the cell or subject is heterozygous at rs1683564. A second RNA molecule and a CRISPR nuclease complex bind to the 3′ end of the ELANE gene. 'Affects double-strand breaks in the UTR region.

[0121] An embodiment of the present invention is a method for inactivating a mutant ELANE allele in a cell, comprising the steps of: The present invention provides uses of the disclosed RNA molecules, compositions of the present invention, or compositions prepared by the methods of the present invention. do.

[0122] An embodiment of the present invention provides a method for the inactivation of a mutant ELANE allele in a cell. , including an RNA molecule of the invention, a composition of the invention, or a composition prepared by a method of the invention. A drug, comprising: an RNA molecule of the present invention, a composition of the present invention, or a drug prepared by the method of the present invention, administered to a cell; The drug is administered by delivering the composition, and the drug is provided.

[0123] Embodiments of the present invention provide a method for the treatment of SCN or CyN in a subject having or at risk of having SCN or CyN. The methods of the present invention, the modified cells of the present invention for treating, ameliorating, or preventing SCN or CyN, The composition of the present invention or the composition prepared by the method of the present invention, or the use of the RNA molecule of the present invention Provides for use.

[0124] An embodiment of the present invention is a method for treating, ameliorating, or preventing SCN or CyN. The present invention relates to an RNA molecule, a composition of the present invention, a composition prepared by a method of the present invention, or a modified A drug containing a mutant cell, which is administered to a subject having or at risk of having SCN or CyN, The RNA molecule of the present invention, the composition of the present invention, the composition prepared by the method of the present invention, or the composition of the present invention The present invention provides a drug that is administered by delivering modified cells of the present invention.

[0125] Embodiments of the present invention include the use of RNA molecules, CRISPR nucleases or CRISPRs of the present invention. R nuclease-encoding sequence and / or tracrRNA molecule or tracrRN To inactivate the sequence encoding the A molecule and the mutant ELANE allele in the cell, RNA molecule, CRISPR nuclease or sequence encoding a CRISPR nuclease and / or delivery of tracrRNA or a sequence encoding a tracrRNA molecule to cells. A kit for inactivating a mutant ELANE allele in a cell, comprising instructions for Provide a

[0126] Embodiments of the present invention include the use of RNA molecules, CRISPR nucleases or CRISPRs of the present invention. R nuclease-encoding sequence and / or tracrRNA molecule or tracrRN A sequence encoding a molecule, and an RNA molecule, CRISP, for treating SCN or CyN. a sequence encoding a CRISPR nuclease or a CRISPR nuclease, and / or a tracr The sequence encoding the RNA or tracrRNA molecule has or contains SCN or CyN. a method for treating SCN or Cyno in a subject, comprising: A kit for this purpose is provided.

[0127] An embodiment of the present invention is a composition of the present invention, a composition prepared by a method of the present invention, or a composition of the present invention. The modified cells of the invention and the method for delivering a composition to the cells to inactivate the ELANE gene in the cells. - A kit for inactivating a mutant ELANE allele in a cell, comprising instructions for to provide.

[0128] An embodiment of the present invention is a composition of the present invention, a composition prepared by a method of the present invention, or a composition of the present invention. The modified cells of the invention, and the compositions and methods of the invention for treating SCN or CyN or a composition prepared by administering to a patient a recombinant human or human animal that has or has SCN or CyN. a method for treating SCN or Cyno in a subject, comprising: We provide a kit for this purpose.

[0129] definition Unless otherwise specified, technical and / or scientific terms used herein are The same meaning as commonly understood by one skilled in the art to which the invention pertains Methods and materials similar or equivalent to those described herein may be used in conjunction with the present invention. Exemplary methods and / or methods that may be used in the practice or testing of embodiments of the present invention are also provided. The materials are as described below. In case of conflict, the patent specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and are not intended to be necessarily limiting. It is not intended to be a diagram.

[0130] The terms "a" and "an" as used above and elsewhere in this specification refer to an enumeration. The use of the singular should be understood to refer to "one or more" of the elements being described. It will be clear to one skilled in the art that the plural forms are included unless expressly stated otherwise. Thus, the terms "a," "an," and "at least one" are used interchangeably in this application. Used in Noh.

[0131] For the purpose of better understanding the present teachings and without limiting the scope of the present teachings in any way, Unless otherwise indicated, amounts, percentages or ratios, and other terms used in this specification and claims All figures expressing numerical values ​​are to be modified in all instances by the term "translation." Therefore, unless specifically indicated to the contrary, the following specification The numerical parameters set forth in the specification and appended claims are intended to be illustrative and not restrictive of the desired results sought to be obtained. These are approximations that may vary depending on the properties. At a minimum, each numerical parameter should be reported as accurate as possible. By taking into account the number of significant figures obtained and applying normal rounding methods, should also be interpreted.

[0132] Unless otherwise stated, any condition or relationship specific to a feature or group of features of an embodiment of the present invention may be modified. Adjectives such as "substantially" and "approximately" are used to indicate that this condition or characteristic is consistent with the specification in which it is intended. The meaning and understanding of the process as being within the acceptable range for the application of the embodiment. Unless otherwise indicated, the word "or" in this specification and claims is used in an exclusive sense. be considered an inclusive "or" rather than an exclusive "or" and must be present in at least one or more of the items it joins. indicates any combination.

[0133] In the description and claims of this application, the words "comprise" and "include" are used interchangeably. The verbs "ude" and "have" and their conjugations do not necessarily refer to the object or group of objects of the verb. Indicates that the list is not exhaustive, that is, that the components, elements, or parts of the object or object group of a verb Other terms used herein are understood to mean those terms that are well known in the art. Defined by meaning.

[0134] As used herein, the term "heterozygous single nucleotide polymorphism" or "SNP" refers to a heterozygous single nucleotide polymorphism. refers to the position of a single nucleotide in the genome that differs between pairs of chromosomes within a cluster. When used in the context of The nucleotide sequence is called the reference (REF), wild type (WT), common, or major form. Nucleotide bases that do not match are called alternative (ALT), minor, rare or variant forms. can be.

[0135] The "guide sequence" of the RNA molecule can hybridize to a specific target DNA sequence. The guide sequence portion refers to a nucleotide sequence, for example, a target sequence over the length of the guide sequence portion. The DNA sequence of interest is a nucleotide sequence that is completely complementary to the DNA sequence of interest. In this embodiment, the guide arrangement has a length of 17, 18, 19, 20, 21, 22, 23 or 24 nucleotides, or approximately 17-24, 18-22, 19-22, or 18-20 in length or 17 to 20 nucleotides. The guide sequence is completely complementary to the DNA sequence targeted by the guide sequence. It forms a complex with the CRISPR nuclease, which acts as the DNA targeting moiety of the RISPR complex. The DNA molecule having the guide sequence may be a part of an RNA molecule capable of When present together with RISPR molecules, the RNA molecule specifically targets the CRISPR nuclease. Each possibility represents a separate embodiment. RNA molecules can be custom designed to target any desired sequence.

[0136] The term "targeted" as used herein refers to a nucleic acid to which an RNA molecule is targeted. The term refers to a guide sequence that preferentially hybridizes to a nucleic acid having a guide sequence. "Targeted" means that a nucleic acid that preferentially hybridizes to a nucleic acid having a targeted nucleotide sequence. However, in addition to hybridization on the target, unintended off-target hybridization may also occur. This is intended to encompass variable hybridization efficiencies, such that lid formation may also occur. When an RNA molecule targets a sequence, the RNA molecule and the CRISPR nuclei It is understood that a complex of nuclease molecules targets this sequence for nuclease activity.

[0137] In the context of targeting a DNA sequence present in multiple cells, this targeting This means that the guide sequence portion of the RNA molecule hybridizes to one or more cellular sequences. and wherein the RNA molecule hybridizes with the target sequence in fewer than all of the plurality of cells. Therefore, it is understood that the hybridization of an RNA molecule with multiple cells is also included. When targeting a sequence, one or more complexes of RNA molecules and CRISPR nucleases are formed. It is understood that the target sequence hybridizes to the target sequence of all cells, and the target sequence of fewer cells. It is understood that the RNA molecule may hybridize to the CRISPR sequence. Associated with hybridization of the nuclease complex to one or more cellular target sequences. to introduce double-strand breaks and hybridize to the target sequence in fewer than all cells. As used herein, the term "modified nucleotide sequence" may refer to a double-stranded break in the target gene. A "cell" is a molecule that hybridizes to a target sequence, i.e., as a result of hybridization on the target. The double-strand breaks were generated by the complex of RNA molecules and CRISPR nuclease. Refers to the cell.

[0138] In an embodiment of the invention, the RNA guide molecule is located at the polymorphic site of the mutant allele. Mutant alleles may be targeted based on the nucleotide base that is present.

[0139] In an embodiment of the invention, the RNA molecule is selected from the group consisting of: The following group SEQ ID NOs: 6, 75, 76, 252, 253, 28 7, 295, 296, 311, 536, 592, 595, 596, 597, 695, 72 9, 737, 812, 839, 915, 947, 1048, 1049, 1070, 107 1, 1169, or the following group SEQ ID NOs: 6, 75, 76, 93, 94, 97, 98, 148, 149, 171, 173, 180, 182, 183, 184 , 187, 188, 213, 232, 234, 249, 252, 253, 264, 272 , 287, 291, 295, 296, 305, 306, 307, 308, 311, 326 , 333, 334, 337, 338, 339, 340, 351, 352, 358, 359 , 378, 379, 385, 388, 399, 408, 410, 419, 420, 426 , 427, 428, 429, 430, 436, 437, 449, 450, 465, 468 、476、477、478、480、495、497、499、500、508、511 、521、522、523、524、529、530、532、536、542、545 、546、564、565、566、573、574、583、584、591、592 、595、596、597、598、599、601、602、604、612、613 、616、622、623、634、644、645、658、659、661、670 、671、678、680、681、684、685、688、689、694、695 、714、715、716、722、723、724、729、736、737、739 、740、745、755、756、760、761、769、770、771、772 、775、776、786、787、806、809、812、818、819、821 、822、826、829、830、833、834、839、845、846、861 、862、874、875、876、877、884、888、889、890、891 、893、894、911、912、913、914、915、925、928、930 、931、939、940、942、946、947、948、949、950、957 、972、974、982、994、998、1006、1007、1008、1021 、1022、1026、1027、1028、1031、1032、1034、1035 、1039、1046、1047、1048、1049、1057、1070、1071 、1072、1074、1075、1076、1079、1084、1090、1091 、1093、1094、1095、1112、1113、1116、1117、1118 , 1119, 1121, 1122, 1124, 1140, 1168, 1169, 1170 , 1171, 1179, or the following group SEQ ID NOs: 6, 10, 13 , 14, 19, 21, 22, 23, 24, 25, 26, 29, 30, 34, 35, 36, 39, 42, 43, 44, 45, 46, 47, 48, 49, 50, 52, 53, 54, 5 5, 57, 58, 61, 62, 64, 65, 66, 67, 68, 69, 70, 71, 72 , 73, 74, 75, 76, 82, 86, 87, 88, 89, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 107, 108, 1 09.115, 119, 122, 123, 124, 125, 126, 127, 128, 1 30, 133, 134, 135, 136, 137, 138, 139, 140, 141, 1 42, 143, 144, 148, 149, 150, 152, 153, 155, 156, 1 58, 159, 160, 161, 162, 163, 164, 167, 168, 169, 1 70, 171, 172, 173, 175, 176, 177, 178, 179, 180, 1 81, 182, 183, 184, 187, 188, 189, 190, 191, 192, 1 95, 196, 198, 199, 201, 203, 206, 209, 211, 212, 2 13, 214, 215, 216, 217, 219, 220, 221, 223, 224, 2 25, 226, 227, 232, 233, 234, 236, 237, 238, 240, 2 41, 242, 243, 244, 245, 246, 247, 248, 249, 250, 2 51, 252, 253, 254, 255, 256, 261, 262, 263, 264, 2 65, 266, 267, 269, 270, 271, 272, 273, 274, 275, 2 76、277、281、282、285、286、287、290、291、292、2 93、294、295、296、302、303、305、306、307、308、3 10、311、314、319、323、326、327、328、329、331、3 32、333、334、335、336、337、338、339、340、341、3 43、344、345、346、349、350、351、352、353、354、3 56、357、358、359、360、363、364、366、370、371、3 72、373、374、375、376、377、378、379、380、381、3 82、385、386、387、388、389、390、391、392、393、3 94、395、396、397、399、400、404、405、406、407、4 08、410、411、412、415、417、418、419、420、422、4 23、424、425、426、427、428、429、430、431、432、4 33、435、436、437、440、441、442、443、444、445、4 46、447、449、450、451、452、454、455、456、457、4 60、461、462、464、465、466、467、468、469、470、4 71、474、475、476、477、478、479、480、483、484、4 85、486、488、489、491、492、493、494、495、496、4 97、498、499、500、501、502、504、505、506、508、5 09、510、511、513、514、517、518、519、520、521、5 22、523、524、525、526、527、528、529、530、531、5 32、533、536、537、538、539、540、541、542、543、5 44、545、546、547、548、549、550、552、553、554、5 55、556、557、558、559、560、561、562、563、564、5 65、566、567、568、569、570、571、573、574、577、5 79、580、582、583、584、586、587、588、590、591、5 92、593、595、596、597、598、599、600、601、602、6 04、605、606、607、608、609、610、612、613、614、6 15、616、617、618、619、620、621、622、623、624、6 25、628、629、630、633、634、635、636、637、638、6 39、640、641、644、645、648、650、651、652、653、6 54、655、658、659、660、661、663、664、665、667、6 70、671、672、673、675、676、678、680、681、683、6 84、685、686、688、689、690、691、692、694、695、6 98、700、701、702、703、704、705、706、707、708、7 09、712、713、714、715、716、718、719、720、722、7 23、724、727、728、729、730、731、732、733、734、7 35、736、737、738、739、740、742、743、744、745、7 46、747、748、749、753、754、755、756、757、758、7 59、760、761、762、763、764、767、769、770、771、7 72、773、775、776、778、779、780、781、786、787、7 88、789、790、791、792、794、795、798、800、801、8 05、806、807、808、809、811、812、813、814、815、8 16、818、819、820、821、822、823、826、829、830、8 31、832、833、834、835、836、837、838、839、843、8 44、845、846、849、850、852、853、854、855、856、8 57、858、861、862、863、864、865、866、867、868、8 70、871、872、874、875、876、877、878、879、880、8 81、882、883、884、886、887、888、889、890、891、8 93、894、895、896、897、898、899、901、902、903、9 05、906、907、908、909、910、911、912、913、914、9 15、916、917、920、921、925、926、927、928、929、9 30、931、932、933、934、935、936、937、939、940、9 42、943、945、946、947、948、949、950、951、952、9 53、954、955、956、957、958、960、961、962、963、9 64、965、966、967、968、969、972、974、975、976、9 78、979、982、983、984、988、989、990、991、992、9 93、994、996、997、998、1001、1002、1003、1004、1 005、1006、1007、1008、1009、1010、1011、1012、1 013、1014、1015、1017、1018、1019、1020、1021、1 022、1023、1024、1026、1027、1028、1029、1030、1 031、1032、1033、1034、1035、1036、1037、1038、1 039、1040、1042、1043、1044、1045、1046、1047、1 048、1049、1050、1051、1052、1053、1054、1055、1 056、1057、1058、1061、1062、1063、1064、1069、1 070、1071、1072、1073、1074、1075、1076、1077、1 078、1079、1080、1081、1082、1083、1084、1086、1 090、1091、1093、1094、1095、1097、1099、1100、1 101、1102、1103、1104、1105、1107、1108、1110、1 111、1112、1113、1114、1115、1116、1117、1118、1 119、1120、1121、1122、1123、1124、1126、1127、1 128、1131、1132、1133、1134、1135、1136、1137、1 138、1139、1140、1142、1143、1144、1145、1147、1 148、1149、1151、1152、1153、1154、1155、1156、1 158、1159、1160、1162、1164、1165、1166、1167、1 168、1169、1170、1171、1172、1173、1175、1176、1 17-20 adjacent items listed in 179, 1180, 1181, 1182, 1183 The guide sequence portion has 17 to 20 nucleotides in the sequence of nucleotides In any embodiment of the present invention, the guide sequence portion of the RNA molecule is SEQ ID NO:1. to any single sequence from 1192 to 1192, or to any single sequence from the above group of sequences, It is understood that the sequence may include any of the 17 to 20 contiguous nucleotides described.

[0140] As used herein, "contiguous nucleotides" as set forth in a SEQ ID NO: "SEQ ID NO: 1" means a sequence of nucleotides in the order set forth in the SEQ ID NO: 1 without any intervening nucleotides. It refers to a sequence of nucleotides.

[0141] In an embodiment of the invention, the guide sequence may be 20 nucleotides in length. Preferably, 20 contiguous nucleotides set forth in any one of SEQ ID NOs: 1 to 1192 are In an embodiment of the present invention, the nucleotide sequence is 20 nucleotides. However, the guide sequence portion may be shorter than 20 nucleotides in length. In embodiments, the guide sequence portion is 17, 18, or 19 nucleotides in length. In such an embodiment, the guide array portion may be any of SEQ ID NOs: 1 to 119. 2. A sequence of 17 to 20 contiguous nucleotides as set forth in any one of It may consist of 17, 18 or 19 nucleotides. For example, The sequence of 17 adjacent nucleotides listed in The guide sequence portion may consist of any one of the following nucleotide sequences (adjacent Nucleotides excluded from the sequence are crossed out). TIFF2024160277000001.tif44162

[0142] In an embodiment of the invention, the guide sequence portion is greater than 20 nucleotides in length. For example, in an embodiment of the present invention, the guide arrangement may have lengths of 21, 22, 23 In such an embodiment, the guide sequence portion may be 24 nucleotides or 24 nucleotides. is a sequence of 20 contiguous nucleotides set forth in any one of SEQ ID NOs: 1 to 1192. 20 nucleotides of the nucleotide sequence, the 3' end of the target sequence, and the 5' end of the target sequence or both adjacent nucleotides or additional nucleotides that are completely complementary to the sequence of nucleotides. Contains octide.

[0143] In an embodiment of the present invention, a CRISPR nuclease and an RNA comprising a guide sequence portion The molecule is a CRISPR complex that binds to the target DNA sequence and causes cleavage of the target DNA sequence. CRISPR nucleases such as Cpfl further enhance the tracrRNA structure. Without the aid of a molecule, CRISPR complexes containing CRISPR nuclease and RNA molecules are formed. Alternatively, a CRISPR nuclease, such as Cas9, may be used to A CRISPR complex may be formed between the enzyme, the RNA molecule, and the tracrRNA molecule. .

[0144] In an embodiment of the invention, the RNA molecule further comprises the sequence of a tracrRNA molecule. Such an embodiment may be a combination of a guide portion of an RNA molecule and a transactivating crRNA. It may also be designed as a synthetic fusion of (tracrRNA). (Jinek (2012) S (See Science). Embodiments of the present invention also provide separate tracrRNA molecules and guide Separate RNA molecules containing the sequence may be used to form a CRISPR complex. In such an embodiment, the tracrRNA molecule binds to the RNA molecule via base pairing. Hybrids may be formed, which may be advantageous in certain applications of the invention described herein. It is possible.

[0145] The term "tracr mate sequence" refers to a sequence that hybridizes with tracrRNA through base pairing. The tracrRNA molecule forms a complex that is sufficiently compatible with the tracrRNA molecule to promote CRISPR complex formation. (See US8906616). In an embodiment of the present invention, The fragment may further comprise a portion having a tracr mate sequence.

[0146] According to embodiments of the present invention, the RNA molecule may be 300, 290, 280, 270, 2 60, 250, 240, 230, 220, 210, 200, 190, 180, 170, 1 up to 60, 150, 140, 130, 120, 110 or 100 nucleotides Each possibility represents a separate embodiment. In embodiments of the invention, the RNA molecule are 17–300 nucleotides in length, 100–300 nucleotides in length, and Length: 150-300 nucleotides, Length: 200-300 nucleotides, Length: Even if it is 100-200 nucleotides or 150-250 nucleotides in length Each possibility represents a separate embodiment.

[0147] For purposes of this disclosure, a "gene" refers to a region of DNA that encodes a gene product, and It includes all DNA regions that regulate the synthesis of gene products, and such regulatory sequences are coding and / or Thus, a gene may or may not be adjacent to a promoter sequence, Translation regulatory sequences such as terminators, ribosome binding sites and internal ribosome entry sites, enhancer, silencer, insulator, boundary region, replication origin, matrix binding These include, but are not necessarily limited to, gene locus control regions and gene locus control regions.

[0148] "Eukaryotic" cells include fungal cells (such as yeast), plant cells, animal cells, mammalian cells, and human This includes, but is not limited to, cells.

[0149] As used herein, the term HSPC refers to both hematopoietic stem cells and hematopoietic stem progenitor cells. Non-limiting examples of stem cells include bone marrow cells, myeloid progenitor cells, multipotent progenitor cells, lineage Contains restricted progenitor cells.

[0150] As used herein, a "progenitor cell" refers to a cell derived from a stem cell and possessing mitotic competence and Multipotent (e.g., the ability to differentiate or develop into more than one, but not all, types of mature lineage of cells) As used herein, "hematopoietic stem cells" refers to lineage cells that possess the ability to produce hematopoietic stem cells. " or "erythropoiesis" refers to the production of various types of blood cells (e.g., erythrocytes, megakaryocytes, myelocytes (e.g., For example, monocytes, macrophages, and neutrophils) and lymphocytes) and in the body (such as in the bone marrow). Refers to other elements that are formed.

[0151] The term "nuclease" as used herein refers to a nucleotide subunit of a nucleic acid. Nucleases are enzymes that can cleave the phosphodiester bonds between proteins. It may be isolated or derived from a natural source. The natural source may be any living organism. Alternatively, the nuclease may be a modified or synthetic protein that retains the ability to cleave phosphodiester bonds. Nucleases, such as CRISPR nucleases, can be used to Change can be achieved.

[0152] In an embodiment of the invention, the RNA molecule is present in a mutant allele of the ELANE gene. The RNA molecule is designed to target the heterozygous polymorphic site in the ELANE gene. Nucleotide base at the heterozygous polymorphic site present in the mutant allele, REF or AL Targeting T.

[0153] The present disclosure provides a method for identifying a gene encoding a mutant protein in which one allele encodes a mutant protein whose mutation results in a disease phenotype. One allele carries a mutation (the "mutated allele"), while the other allele encodes a functional protein. to distinguish between two alleles of a gene ("functional alleles"). at least one naturally occurring nucleotide difference or genetic polymorphism (single nucleotide polymorphism (SNP) The method knocks out the expression of a mutant protein and inhibits its function. In some embodiments, the method further comprises allowing expression of a target protein. The method is for treating, ameliorating, or preventing a dominant-negative genetic disorder.

[0154] Embodiments of the present invention involve the identification of dominant mutant alleles in a given cell or subject. The present invention provides a method that utilizes at least one heterozygous SNP in an expressed gene. In certain embodiments, the SNPs utilized may or may not be associated with a disease phenotype. In an embodiment of the invention, an RNA molecule comprising a guide sequence is heterozygous SNPs, and therefore different nucleotides in the functional alleles of the gene. Targeting mutant alleles of genes by targeting nucleotides with nucleotide bases Let's say.

[0155] According to an embodiment of the present invention, the first RNA molecule comprises an exon or promoter of the ELANE gene. The first RNA molecule targets a first heterozygous SNP present in the EL promoter. The nucleotide base of the first SNP present in the mutant allele of the ANE gene, REF or The second RNA molecule targets ALT and the second RNA molecule targets the same or a different exon of the ELANE gene. or a second heterozygous SNP present in an intron, and the second RNA molecule The nucleotide base of the second SNP present in the mutant allele of the ELANE gene, REF or ALT, or the second RNA molecule targets a mutant allele or a functional allele. It targets non-coding sequences present in both genes.

[0156] According to an embodiment of the present invention, the first RNA molecule or the first and second RNA molecules are The promoter region, initiation codon, or untranslated region (UTR) of the ANE gene Targeting the telozygous SNP, the RNA molecule is present in the mutant allele of the ELANE gene. The nucleotide base of the SNP to be targeted is REF or ALT.

[0157] According to an embodiment of the present invention, the first RNA molecule or the first and second RNA molecules are At least part of the promoter and / or the start codon and Targeting a portion of the UTR.

[0158] According to an embodiment of the present invention, the first RNA molecule comprises a portion of a promoter, an ELANE gene, The first heterozygous SNP located in the promoter of the gene or in the promoter of the ELANE gene A second RNA molecule targets a heterozygous SNP located upstream of the motor and encodes a second Target a heterozygous SNP, and this second heterozygous SNP is The SNP is located downstream of the ELANE gene, and the promoter and UTR of the ELANE gene are also involved. The first RNA molecule is located in an intron or exon of the ELANE gene. The nucleotide base of the first SNP, REF or ALT, present in the allele is targeted, and the second SNP is targeted. The second RNA molecule contains the nucleotide sequence of the second SNP present in the mutant allele of the ELANE gene. Targeting the octide base, REF or ALT.

[0159] According to an embodiment of the present invention, the first RNA molecule comprises a promoter of the ELANE gene, Targeting heterozygous SNPs located upstream of the promoter or in the UTR, The nucleotide base of the SNP present in the mutation-inducing gene of the ELANE gene, REF or The second RNA molecule targets ALT and identifies the mutant allele and function of the ELANE gene. It is designed to target sequences present in both introns of the male allele.

[0160] According to an embodiment of the present invention, the first RNA molecule comprises a mutant allele of the ELANE gene. or functional alleles, targeting the upstream sequence of the promoter present in both alleles, and The NA molecule targets heterozygous SNPs present at any position in the ELANE gene, The second RNA molecule encodes the nucleotide sequence of the SNP present in the mutant allele of the ELANE gene. Targets the base, REF, or ALT.

[0161] According to an embodiment of the present invention, exons containing disease-causing mutations are removed from mutant alleles. the first RNA molecule or the first and second RNA molecules are and targeting a region adjacent to all or part of the xon.

[0162] According to an embodiment of the present invention, the entire open reading frame of a gene, multiple exons, Methods are provided that include removing a portion of the gene, or removing the entire gene.

[0163] According to an embodiment of the present invention, the first RNA molecule is an exon or promoter of the ELANE gene. The second RNA molecule targets the first heterozygous SNP present in the motor, and the second RNA molecule is expressed in the ELA A second heterozygous S present in the same or a different exon or intron of the NE gene The second RNA molecule targets NP and binds to the first RNA present in the mutant allele of the ELANE gene. The nucleotide bases of the two SNPs, REF or ALT, are targeted, or the second RNA sequence is The offspring are endogenous to the mutant allele and the functional allele of the ELANE gene. Targeting the sequence of ron.

[0164] According to an embodiment of the present invention, the first RNA molecule or the first and second RNA molecules are Targeting alternative splicing signal sequences between exons and introns of alleles do.

[0165] According to an embodiment of the present invention, the second RNA molecule comprises a mutant allele of the ELANE gene. It targets sequences present in both the genomic and functional alleles.

[0166] According to an embodiment of the invention, the second RNA molecule targets an intron.

[0167] According to an embodiment of the present invention, a gene encoding a gene that is modified by the error-prone non-homologous end joining (NHEJ) mechanism The mutant allele is subjected to an insertion or deletion, resulting in a frameshift in the sequence of the mutant allele. A method is provided that includes:

[0168] According to an embodiment of the present invention, the frameshift is inactivating or knocking out the mutant allele. Produces an out.

[0169] According to an embodiment of the present invention, a frameshift results in a premature stop code in the mutant allele. A new file is created.

[0170] According to an embodiment of the present invention, a frameshift results in a nonsense transcript of the mutant allele. Mutation-dependent mRNA decay occurs.

[0171] According to an embodiment of the present invention, the inactivation or treatment of a mutant allele encodes The truncated proteins and functional proteins encoded by the functional alleles are produced. Jiru.

[0172] The compositions and methods of the present disclosure may be used to treat, prevent, ameliorate, or slow the progression of SCN or CyN. It may be used for this purpose.

[0173] In some embodiments, the cells contain a promoter region, an initiation codon, and a nucleotide sequence encoding the ELANE gene. RNA molecules targeting heterozygous SNPs in the donor or untranslated region (UTR) The RNA molecule inactivates the mutant allele of the ELANE gene by delivering The nucleotide bases of the SNPs present in different alleles, REF or ALT, are targeted.

[0174] In some embodiments, the mutant allele removes at least a portion of the promoter. inactivation by removing the start codon and / or part of the UTR In some embodiments, the method of inactivating a mutant allele comprises at least In such an embodiment, one RNA fragment may be removed. The A molecule is a first gene located in the promoter of the ELANE gene or upstream of the promoter. Another RNA molecule is designed to target the heterozygous SNP, while another RNA molecule targets the second heterozygous SNP. This second heterozygous SNP is downstream of the first SNP and is associated with ELA It is present in the promoter, UTR, intron, or exon of the NE gene; or One RNA molecule is located either in the promoter of the ELANE gene or upstream of the promoter. It is designed to target heterozygous SNPs located in the UTR of the ELANE gene. and the separate RNA molecules may comprise a mutant allele and a functional allele of the ELANE gene. Alternatively, the target sequence may be designed to target sequences present in both introns of a single RN. The A molecule is located upstream of the promoter present in both the mutant and functional alleles. Other guides may be designed to target sequences, such as exons of the ELANE gene, Located anywhere in the ELANE gene, such as introns, UTRs, or downstream of the promoter The RNA molecule was designed to target the heterozygous SNP in the ELANE gene. The nucleotide base of the SNP present in the mutant allele, REF or ALT, is targeted.

[0175] In some embodiments, the method of inactivating a mutant allele comprises: exon skipping, which includes removing an exon containing a disease-causing mutation from To remove the exon containing the disease-causing mutation of the mutant allele, Two RNA molecules are required that target regions flanking all or part of an exon in the Removal of the exon containing the disease-causing mutation retains some or all of the wild-type activity. Eliminates the disease-causing activity of a protein while allowing expression of the remaining protein product. As an alternative to single exon skipping, multiple exons, The entire open reading frame or gene may be inserted into the region desired to be excised. Two adjacent RNA molecules can be used to excise.

[0176] In some embodiments, the method of inactivating a mutant allele comprises combining two RNA molecules. The method includes delivering an RNA molecule to a cell, the RNA molecule comprising: The RNA molecule targets the first heterozygous SNP present in the promoter, ELAN The nucleotide base of the first SNP present in the mutant allele of the E gene, REF or AL The other RNA molecule targets T and targets the same or a different exon or intron of the ELANE gene. The RNA molecule targets a second heterozygous SNP present in the nucleus of the ELANE gene. The nucleotide base of the second SNP present in the mutant allele of the gene, REF or ALT, The targeting or second RNA molecule may target both the mutant allele and the functional allele. It targets sequences in existing introns.

[0177] In some embodiments, the RNA molecule is converted to a mutant allele by a CRISPR nuclease. It targets alternative splicing signal sequences between exons and introns of genes and This is used to disrupt the alternative splicing signal sequence of the mutant allele. .

[0178] Any one or combination of the above strategies for inactivating mutant alleles can be used in the present invention. May be used in the context of the invention.

[0179] Additional strategies may be used to inactivate mutant alleles. In certain embodiments, the RNA molecule is transfected with a CRI to generate a double-strand break (DSB). Targeting SPR nucleases to exons or splice sites of mutant alleles to identify errors Nucleotides are inserted or deleted by the prone non-homologous end joining (NHEJ) mechanism, resulting in mutations Used to create a frameshift mutation in an allele. Therefore, (1) the mutant allele is terminated by the creation of a premature stop codon in the mutant allele. may be inactivated or knocked out to create a truncated protein, or (2) The transcript of the mutant allele may undergo nonsense-mediated mRNA decay. In some embodiments, one RNA molecule encodes a CRISPR nuclease that encodes a mutant allele. It is used to target the promoter of

[0180] In some embodiments, the method of inactivating a mutant allele comprises the step of: Proteins / peptides, proteins / peptides that can activate / enhance the activity of proteins The production of functional proteins can be achieved by providing small molecules such as nucleic acids or chemicals that encode the proteins. Further, it includes enhancing the activity.

[0181] According to some embodiments, the present disclosure provides a method for the detection of RNA-mediated catalysis, such as CRISPR nucleases. Binds / associates with DNA nucleases and / or CRISPR nucleases RNA-guided DNA nucleases, such as ribosomal RNA nucleases, are introduced into mutant alleles of the gene of interest. At least one nucleotide differs between the nucleotide and the functional allele (heterozygous SN P) (e.g., sequences of mutant alleles that are not present in functional alleles) The present invention provides an RNA molecule that can

[0182] In some embodiments, the method further comprises alleloselectively isolating a mutant allele of a gene of interest. contact with a CRISPR nuclease, such as a gene-specific RNA molecule and a Cas9 protein CRISP steps, including the steps of: R nuclease binds at least the nucleotide sequence of a functional allele of a gene of interest. The nucleotide sequence of a mutant allele of a gene of interest that differs by only one nucleotide The mutant allele binds to the target gene, thereby altering or knocking out the mutant allele.

[0183] In some embodiments, the allele-specific RNA molecule and the CRISPR nuclei In some embodiments, the enzyme is introduced into the cell encoding the gene of interest. In some embodiments, the cells encoding the gene of interest are in a mammalian subject. Thus, the cells encoding the gene of interest are in the plant.

[0184] In some embodiments, the cleaved mutant allele comprises an error-prone non-homologous end. The NHEJ mechanism causes insertions or deletions (indels) and the alignment of mutant alleles. In some embodiments, the generated frameshift is In some embodiments, the mutation results in the inactivation or knockout of the mutant allele. In this case, the resulting frameshift creates a premature stop codon in the mutant allele. In such an embodiment, the method further comprises the step of: The truncated protein encoded by the allele and the function encoded by the functional allele In some embodiments, the methods of the present invention are used to identify mutant proteins. The frameshift generated in the allele results in a nonsense mutation in the transcript of the mutant allele. Dependent mRNA decay mechanisms occur.

[0185] In some embodiments, the mutant allele is a member of the "neutrophil elastase" gene (E In some embodiments, the RNA molecule is an allele of S ELANE genes coexist / are associated with mutations associated with CN or CyN genetic disorders In some embodiments, the RNA molecule targets a heterozygous SNP in a gene. Heterozygous SNPs in the ELANE gene were targeted, and heterozygosity of the above SNPs was assessed in the population. In an embodiment of the invention, the REF nucleotide is The mutant alleles in each individual subject are prevalent, but the functional alleles are not prevalent. In an embodiment of the present invention, the ALT nucleotide is selected from the mutation pairs of the individual subject to be treated. It is prevalent in the isogenic allele but not in the functional allele. In this method, disease-causing mutations within the mutant ELANE gene are targeted.

[0186] In an embodiment of the invention, heterozygous SNPs are associated with an ELANE-associated disease phenotype. In an embodiment of the present invention, the heterozygous SNP is In an embodiment of the invention, the SNP is associated with an ELA-associated disease phenotype. Not associated with NE-related disease phenotypes.

[0187] In some embodiments, the heterozygous SNP is located within an exon of the gene of interest. In such embodiments, the guide sequence portion of the RNA molecule is It may be designed to target an exon of

[0188] In some embodiments, the heterozygous SNP is located in an intron of the gene of interest. In some embodiments, the heterozygous SNP is located within an intron or exon. In some embodiments, the heterozygous The SNP is at the PAM site of the gene of interest.

[0189] Those skilled in the art will appreciate that in each of the embodiments of the present invention, individually, each of the RNA molecules of the present invention: to the target genomic DNA sequence of interest adjacent to the protospacer adjacent motif (PAM) Form complexes with nucleases, such as related CRISPR nucleases The nuclease then mediates cleavage of the target DNA. Thus, in an embodiment of the present invention, The guide sequence and RNA molecule of the present invention are 1, 2, 3, 4, 5, 6, 7 from the PAM site. , 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , targeting a position 22, 23, 24, 25, 26, 27, or 28 nucleotides upstream or downstream It may also be possible to use the following.

[0190] Therefore, in embodiments of the present invention, nucleases, such as CRISPR nucleases, The RNA molecule of the present invention complexed with the enzyme is located 1, 2, 3, 4, 5, 6 from the target site. ,7,8,9,10,11,12,13,14,15,16,17,18,19,20, 21, 22, 23, 24, 25, 26, 27, 28 Alleles upstream or downstream of genes Those skilled in the art will recognize that heterozygous polymorphic sites exist and may affect double strand breaks, thereby defining the target. If used for the purpose of It is understood that the present invention may be designed to affect double-strand breaks by targeting only nucleotide bases. It will.

[0191] If the heterozygous polymorphic site is within the PAM site, the RNA molecule 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 1 7, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27 or 28 nucleotides The RNA molecule and the nuclease may be designed to target a sequence upstream or downstream of the target. The complex is composed of one of the REF or ALT nucleotide bases at the heterozygous polymorphic site of the PAM site. designed to target only one end and affect cleavage at the PAM site, e.g., tracrRN A is a nucleotide sequence that targets one of the REF or ALT nucleotide bases at the heterozygous polymorphic site. It is understood that the design is as follows.

[0192] In an embodiment of the invention, the RNA molecule comprises a heterozygous nucleotide sequence present in the ELANE gene. RNA molecules and / or RNA molecules and CRISPR designed to target the polymorphic site The nuclease complex binds to the heterozygous polypeptides present in mutant alleles of the ELANE gene. It is designed to target the nucleotide base, REF or ALT, of the target site.

[0193] In an embodiment of the present invention, the RNA molecule, composition, method, cell, kit or drug is Utilized to treat subjects with disease phenotypes resulting from telozygous ELANE genes. In an embodiment of the present invention, the disease is SCN or CyN. In some embodiments, the method improves, ameliorate, or prevents a disease phenotype.

[0194] In an embodiment of the present invention, the RNA molecule, composition, method, cell, kit or drug of the present invention The method is used in combination with a second treatment for SCN or CyN to treat a subject. In an embodiment of the present invention, the RNA molecule, composition, method, cell, kit or drug of the present invention The agent may be administered before, during, and / or after the administration of the second treatment. It is given.

[0195] In an embodiment of the present invention, the RNA molecule, composition, method, cell, kit or drug of the present invention The product is administered in combination with granulocyte colony-stimulating factor (G-CSF) therapy.

[0196] The above embodiments include a CRISPR nuclease, an RNA molecule(s), and a tracrRN. A molecule is effective in a target or cell at the same time. CRISPR, RNA molecule ( The tracrRNA molecule and the tracrRNA molecule can be delivered substantially simultaneously or at different times. For example, this can include RNA molecules and / or Before the tracrRNA molecule is substantially present in a subject or cell, the CRISPR nuclease The present invention includes delivering an enzyme to a subject or cell.

[0197] According to an embodiment of the present invention, a mutant allele of the ELANE gene is inactivated in a cell. 1. A method for producing a medicament for use in a method for producing a medicament for a patient, the method comprising a) ELANE gene mutation associated with SCN or CyN, rs104l48 37, rs3761005, rs1683564, rs9749274, rs74002 l, rs201048029, rs199720952, rs2859l229, rs7 l335276, rs58082l77, rs3826946, rs104l3889, rs761481944, rs376l008, rs10409474, rs376l0 07, rs17216649, rs10469327, rs8107095, rs104 one of the ELANE genes selected from the group consisting of rs78302854 and rs24470 or selecting cells that are heterozygous at multiple polymorphic sites; b) In cells a CRISPR nuclease or a sequence encoding a CRISPR nuclease, and a first RNA molecule comprising a guide sequence portion having 17 to 20 nucleotides; introducing a composition, The complex of CRISPR nuclease and the first RNA molecule binds to the ELANE gene of the cell. affecting double-strand breaks in mutant alleles of ELANE but not the functionality of the cellular ELANE gene. introducing a double-strand break in the isogenic gene, thereby inactivating a mutant allele of the ELANE gene in a cell. do.

[0198] According to an embodiment of the present invention, a mutant allele of the ELANE gene is inactivated in a cell. 1. A method for producing a medicament for use in a method for producing a medicament for a patient, the method comprising a) ELANE gene mutation associated with SCN or CyN, rs104l48 37, rs3761005, rs1683564, rs9749274, rs74002 l, rs201048029, rs199720952, rs2859l229, rs7 l335276, rs58082l77, rs3826946, rs104l3889, rs761481944, rs376l008, rs10409474, rs376l0 07, rs17216649, rs10469327, rs8107095, rs104 one of the ELANE genes selected from the group consisting of rs78302854 and rs24470 or selecting cells that are heterozygous at multiple polymorphic sites; b) In cells a CRISPR nuclease or a sequence encoding a CRISPR nuclease, and a first RNA molecule comprising a guide sequence portion having 17 to 20 nucleotides; introducing a composition, The complex of CRISPR nuclease and the first RNA molecule binds to the ELANE gene of the cell. affecting double-strand breaks in mutant alleles of the ELANE gene, but not functional alleles of the ELANE gene a step of cleaving the double-stranded DNA fragment without affecting the double-stranded break in the DNA fragment, The method further comprises providing a guide sequence capable of forming a complex with a CRISPR nuclease. and introducing a second RNA molecule comprising a CRISPR nucleic acid fragment. The complex with ribosomal enzyme affects a second double-strand break in the ELANE gene, thereby inactivating a mutant allele of the ELANE gene in a cell. do.

[0199] According to an embodiment of the present invention, a cell containing an E. coli having a mutation associated with SCN or CyN is A method for inactivating a mutant allele of a LANE gene, comprising: 4l4837, rs3761005, rs1683564, rs9749274, rs7 4002l, rs201048029, rs199720952, rs2859l229 , rs7l335276, rs58082l77, rs3826946, rs104l3 889, rs761481944, rs376l008, rs10409474, rs3 76l007, rs17216649, rs10469327, rs8107095, r ELANE genes selected from the group consisting of s10424470 and rs78302854 the offspring are heterozygous at one or more polymorphic sites, and the method comprises: to cells a CRISPR nuclease or a sequence encoding a CRISPR nuclease, and a first RNA molecule comprising a guide sequence portion having 17 to 20 nucleotides; introducing a composition, The complex of CRISPR nuclease and the first RNA molecule encodes a mutation in the ELANE gene. affecting or introducing a double-strand break in the allele, thereby inactivating a mutant allele of the ELANE gene in a cell. do.

[0200] According to an embodiment of the present invention, a cell is provided with an ELANE gene associated with SCN or CyN. The mutations rs104l4837, rs3761005, rs1683564, and rs 9749274, rs74002l, rs201048029, rs199720952 , rs2859l229, rs7l335276, rs58082l77, rs3826 946, rs104l3889, rs761481944, rs376l008, rs1 0409474, rs376l007, rs17216649, rs10469327, Selected from the group consisting of rs8107095, rs10424470 and rs78302854 A selected ELANE gene that is heterozygous at one or more polymorphic sites in the ELANE gene. 1. A method for inactivating a mutant allele of a gene, the method comprising: to cells a CRISPR nuclease or a sequence encoding a CRISPR nuclease, and a first RNA molecule comprising a guide sequence portion having 17 to 20 nucleotides; introducing a composition, The complex of CRISPR nuclease and the first RNA molecule encodes a mutation in the ELANE gene. affecting double-strand breaks in the allele, The method further comprises providing a guide sequence capable of forming a complex with a CRISPR nuclease. and introducing a second RNA molecule comprising a CRISPR nucleic acid fragment. The complex with ribosomal enzyme affects a second double-strand break in the ELANE gene, thereby inactivating a mutant allele of the ELANE gene in a cell. do.

[0201] In an embodiment of the invention, a complex of a CRISPR nuclease and a first RNA molecule affects double-strand breaks in mutant alleles of the ELANE gene in cells, but not in cells It does not affect double-strand breaks in functional alleles of the ELANE gene.

[0202] In an embodiment of the invention, the cells also contain rs104l4837, rs376l005 , rs1683564, rs9749274, rs74002l, rs20l04802 9, rs199720952, rs28591229, rs7l335276, rs58 082l77, rs3826946, rs104l3889, rs76l48l944, rs376l008, rs10409474, rs376l007, rs172l664 9, rs10469327, rs8l07095, rs10424470 and rs783 02854. At least one further polymorphism in the ELANE gene selected from the group consisting of Heterozygous at the site.

[0203] In an embodiment of the present invention, the ELANE gene mutation associated with SCN or CyN is Cells with ELANE mutations and / or suffer from SCN or CyN Therefore, cells having the ELANE gene mutation can be selected. This may include selecting a subject who has an ELANE gene mutation. In a further embodiment, selecting the cells comprises selecting cells from a subject having an ELANE gene mutation. In an embodiment of the present invention, the composition of the subject invention may comprise a step of selecting the cells. Introducing the composition into cells involves administering the composition of the present invention to a subject suffering from an ELANE gene mutation. The method may include introducing the vector into a cell of the invention.

[0204] Thus, in an embodiment of the present invention, a mutant allele of the ELANE gene of interest in a cell The method involves inactivating the ELANE gene that causes SCN or CyN. The mutations were rs104l4837, rs376l005, rs1683564, and rs 9749274, rs74002l, rs20l048029, rs199720952 , rs2859l229, rs71335276, rs58082l77, rs3826 946, rs104l3889, rs76l48l944, rs376l008, rs1 0409474, rs376l007, rs172l6649, rs10469327, From the group consisting of rs8107095, rs10424470 and rs78302854n Selecting subjects who are heterozygous at one or more polymorphic sites in the selected ELANE gene. A method is provided, comprising the steps of:

[0205] Thus, embodiments of the present invention include screening subjects or cells for the ELANE gene. Those skilled in the art will appreciate that, as a non-limiting example, -synthesis, Sanger sequencing, karyotyping, fluorescence in situ hybridization In the ELANE gene, prior art techniques such as ELISA and / or microarray testing It will be readily apparent how to select for mutations. Mutations within the gene are screened by exon sequencing.

[0206] In an embodiment of the present invention, a subject has absolute neutrophil count (ANC) measured in peripheral blood. In an embodiment of the present invention, the patient is diagnosed with SCN or CyN by: SCN is or was diagnosed before the subject reached 6 months of age. In these cases, CyN was diagnosed between 12 and 24 months of age or after 24 months of age. In an embodiment of the present invention, SCN or CyN is a genotype or gene that has been diagnosed as having one or more recurrent leukemias. In an embodiment of the present invention, the diagnosis is made by an SCN or C yN is diagnosed by bone marrow examination, preferably with cytogenetic bone marrow investigation. In an embodiment of the present invention, SCN or CyN is used in anti-neutrophil antibody assays, immunoglobulin assays, and immunoassays. Ig GAM, lymphocyte immunophenotyping, pancreatic markers (serum triglyceride) psinogen and fecal elastase) and fat-soluble vitamin levels (vitamins A, E and D) is diagnosed by one or more of the following diagnostic methods. It is understood that it may be used in conjunction with

[0207] In an embodiment of the present invention, a subject diagnosed with SCN or CyN has a gene encoding the ELANE gene. Exon sequencing is used to identify ELANE pathogenic variants. In further embodiments, the subject is identified as heterozygous for at least one SNP in Table 1. In an embodiment of the present invention, the SN P is one of rs1683564, rsI04l4837, and rs3761005 In an embodiment of the present invention, heterozygosity of a mutant allele of the ELANE gene The nucleotide of the SNP is determined using BAC bio. In the embodiment of the present invention, the appropriate guide is selected according to Table 2. The guide is introduced into cells, such as PBMCs, obtained from a subject, and the cells are transfected with pathogenic ELAN. The reduction in E mutations is measured using next-generation sequencing technology, etc.

[0208] The CR1SPR / Cas9 gene editing system allows us to target nucleases to disease-causing genes. It can target target sites in a sequence-specific manner to combat mutations. HSPCs have the ability to both self-renew and differentiate (Yu, Natanso n, and Dunbar 2016), there is a therapeutic potential. The form applies genome editing to HSPCs.

[0209] In an embodiment of the present invention, the home-grown treatment involves the use of a cell line derived from a patient diagnosed with SCN or CyN. The present invention utilizes autologous CD34+ hematopoietic stem cells edited with CRISPR / Cas9. In some embodiments, the CD34+ cells are derived from bone marrow or peripheral blood mononuclear cells following apheresis in a patient. It is isolated from PBMCs.

[0210] Dominant negative (or compound heterozygous) signs, such as SCN or CyN In this case, the strategy is to edit the mutant allele and target the heterozygous SNP sequence. This avoids cleavage of unmutated alleles or other off-targets. be.

[0211] An embodiment of the present invention includes the following steps. At least one of the SNPs in Table 1 herein below is identified as exhibiting heterozygosity. Selection of patients diagnosed with SCN or CyN. In an embodiment of the present invention, the subject is heterozygous for 104l4837, rs376l005, or rs1683564; Selection of treatment strategies based on identified heterozygous SNP locations in candidate patients. Bone marrow from the subject either by aspiration of peripheral blood or by mobilization and apheresis Obtain HSPC cells from the culture medium, and optionally process (enrich, stimulate) the HSPC cells. (both, etc.) HSPC cells (e.g., by ex vivo electroporation) a CRISPR nuclease or a sequence (e.g., mRNA) encoding the same; The specific sequence of the identified heterozygous SNP of the mutant allele (REF / ALT sequence) Targeted characteristic RNA molecules and Intron 3, intron 4, or introducing a composition comprising a non-characteristic RNA molecule that targets a sequence in the 3'UTR; This allows HSPC cells to be edited to knock out the expression of the mutant allele of ELANE. .and The edited HSPCs are introduced into candidate patients.

[0212] In an embodiment of the invention, CD34+ cells are isolated from bone marrow or peripheral blood following patient apheresis. The bone marrow or PBMCs may be isolated from the afferent cells after HSPC mobilization. In an embodiment of the invention, the apheresis product may be collected from the patient by apheresis. The platelets may be removed by washing the platelets. The CD34+ cell population may be enriched by purification using a system such as a cytochrome P4500 (Cytochrome P4500) or a cytochrome P4500 (Cytochrome P4500) immunochromatography system. In one embodiment, the selected cells are transformed with a mixture of recombinant human cytokines, etc. In an embodiment of the invention, cells may be pre-stimulated ex vivo. In an embodiment of the present invention, the cells may be subjected to stimulation before electroporation. Excited cells (e.g., CD34+ cells), CRISPR nuclease, mRNA, and gRNA were added. In an embodiment of the present invention, the cells may be pre-incubated under defined conditions. RISPR nuclease, mRNA / gRNA mixture or preassembled RNPs (C RISPR nuclease protein (ribonuclease protein and gRNA) In an embodiment of the present invention, the cells are electroporated ex vivo using a PBS containing 100% ethanol. In an embodiment of the invention, the cells are resuspended in the final formulation. In an embodiment of the present invention, the resuspended cells may be loaded into an infusion bag. In an embodiment of the present invention, the bag is frozen down in a controlled rate freezer. The cells may be frozen using a step or stored in vapor phase liquid nitrogen. In embodiments, the product may be administered to the patient by intravenous (IV) administration.

[0213] Dominant genetic disorders Those skilled in the art will be able to identify all heterozygous genetic disorders of any kind (such as dominant genetic disorders). It will be understood that any subject may undergo the methods described herein. In one embodiment, the present invention is directed to a dominant genetic disorder, such as SCN or CyN. It may also be used to target genes involved in, associated with, or causative of In some embodiments, the dominant genetic disorder is SCN or CyN. In some embodiments, the target gene is the ELANE gene (Entrez Gene, gene ID No: 335).

[0214] CRISPR nucleases and PAM recognition In some embodiments, the sequence-specific nuclease is a CRISPR nuclease or a functional variant thereof. The nuclease is an RNA-guided DNA nuclease. In this study, an RNA sequence (Cpfl et al.) that guides an RNA-guided DNA nuclease was used. ) binds to and / or interacts with this RNA-guided DNA nuclease Guided DNA nuclease expression in mutant alleles and their functional counterparts It targets sequences that contain at least one nucleotide that differs between the two (e.g., a SNP). In some embodiments, the CRISPR complex does not further comprise a tracrRNA. In a non-limiting example, the RNA-guided DNA nuclease can be used to generate CRISPR nucleases. Although the enzyme is a dominant mutant allele, there are few differences between the functional allele and the dominant mutant allele. At least one nucleotide may be within the PAM site and / or the RNA molecule may be hybridized. It may be proximal to the PAM site within the region designed to form the lid. The RNA molecule is engineered to bind to a selected target within the genome by methods well known in the art. You will understand that you can operate it like this.

[0215] In an embodiment of the present invention, in a Type II CRISPR system, the mature crRN A is utilized, i.e., as an additional target recognition requirement, the tracrRNA complex recognizes Cas9, etc. The CRISPR nuclease binds to the crRNA and the protospacer adjacent motif (PAM). ) between the protospacer of the target DNA adjacent to the protospacer Target DNA via click base pairing. Then, CRISPR nuclease The enzyme mediates cleavage of the target DNA to create a double-stranded break within the protospacer. The present inventors have demonstrated that each of the engineered RNA molecules of the present invention contains a protospacer adjacent motif (PAM). For example, PAM may be used to associate with a target genomic DNA sequence of interest that is adjacent to the target genomic DNA sequence, including, but not limited to, A good example is Streptococcus pyogenes Cas 9 For WT (SpCAS9), NGG or NAG, where "N" is any nucleobase. , Staphylococcus aureus (SaCas9) NNGRRT for Jejunum Cas9 WT, and NNNVRYM for Jejunum Cas9 WT. NGAN or NGNG for the SpCas9-VQR variant, SpCas9-V NGCG for RER variants and NG for SpCas9-EQR variants AG, Neisseria meningitidis (NmCas9) For Cpfl, use CRISPR such as NNNNGATT or TTTV. It is understood that the sequences are further designed to match sequences associated with the nuclease species. The RNA molecules of the present invention may each be a single CRISPR nucleus or a plurality of different CRISPR nuclei. CRISPR nucleases are designed and used to form complexes in combination with enzymes. Each polynucleotide of interest is synthesized using one or more different PAM sequences. It is designed to target the nucleotide sequence.

[0216] In some embodiments, RNA-guided nucleases, such as CRISPR nucleases, DNA nucleases are used to cut DNA at desired locations in a cell's genome. The most commonly used RNA-guided DNA nuclease is CRI Although derived from the SPR system, other RNA-guided DNA nucleases have also been reported. Contemplated for use in the genome editing compositions and methods described herein See, for example, U.S. Patent Application Publication No. 2015-2016024, the contents of which are incorporated herein by reference. Refer to 0211023.

[0217] The CRISPR systems that can be used in the practice of the present invention are extremely diverse. CRISPR systems can be Type I, Type II, Type III or Type V systems. Non-limiting examples of suitable CRISPR proteins include Cas3, Cas4, Ca s5, Cas5e (or CasD), Cas6, Cas6e, Cas6f, Cas7, C as8al, Cas8a2, Cas8b, Cas8c, Cas9, CaslO, Casl 2a, Casl2b, Casl2c, Casl2d, Casl2d, Casl Od, C asF, CasG, Casli, Csyl, Csy2, Csy3, Csel (or Cas A), Cse2 (or CasB), Cse3 (or CasE), Cse4 (or CasC ), Cscl, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm 5, Csm6, Cmrl, Cmr3, Cmr4, Cmr5, Cmr6, Csbl, Csb 2, Csb3, Csxl7, Csxl4, CsxlO, Csxl6, CsaX, Csx3 , Cszl, Csxl5, Csfl, Csf2, Csf3, Csf4 and Cul966 There is (see e.g. Koonin 2017).

[0218] In some embodiments, the RNA-guided DNA nuclease is a type II C CRISPR nucleases (such as Cas9) derived from the RISPR system. SPR nuclease is a nuclease that binds to Streptococcus pyogenes (Streptococcus pyogenes). s), Streptococcus thermophilus ophilu), Streptococcus sp., yellow Staphylococcus aureus, Neisseria meningitidis ria meningitidis), Treponema denticola (Treponema a denticola), Nocardiopsis dassonbiei (Nocardiop sis dassonvillei), Streptomyces pristinaespiralis ( Streptomyces pristinaespiralis), Streptomyces Streptomyces viridochromogenes nes), Streptomyces viridochromodynes (Streptomyces v iridochromogenes), Streptosporangium roseum (Stre ptosporangium roseum), Streptosporangium roseum ( Streptosporangium roseum), Alicyclobacillus acidi Caldarius (Alicyclobacillus acidocaldarius), Bacillus pseudomycoides, Bacillus selenitireducen s), Exiguobacterium sibiricum ricum), Lactobacillus delbruecki i), Lactobacillus salivarius us), Microscilla marina, Burkholder Burkholderiales bacterium, Polaro Polaromonas naphthalenivora ns), Polaromonas sp., Crocosphaera wat Sony (Crocosphaera watsonii), Cyanotes genus hece sp.), Microcystis aeruginosa (Microcystis ae ruginosa), Synechococcus sp., Ase Acetohalobium arabaticum , Ammonifex degensii, Kaldi Caldicelulosiruptor becscii ), Candidatus Desulfo rudis), Clostridium botulinum, Diff Clostridium difjicile, Finegoldia magna (Finegoldia magna), (Natranaerobius thermophilusNa tranaerobius thermophilus), Pelotomaculum thermopro Pelotomaculum thermopropionicum, reed Acidithiobacillus caldus, Acidithiobacillus ferrooxidans rrooxidans), Allochromatium vinosum m vinosum), Marinobacter sp., Nitto Nitrosococcus halophilus, Nitrosococcus watsoni, shoe Pseudoalteromonas haloplanktis oplankti, Ktedonobacter racemifur racemifer), Methanohalobium ebestigatum (Methanohalob ium evestigatum), Anabaena variabilis (Anabaena va riabilis), Nodularia spumige na), Nostoc sp., Arthrospira maxima rospira maxima), Arthrospira platensis (Arthrospi ra platensis), Arthrospira sp., Lyngbya sp., Microcoleus xonoplastes rocoleus chthonoplastes), Oscillatoria atoria sp.), Petrotoga mobilis (Petrotoga mobili s), Thermosipho africanus, Acaryochloris marina, Francisse Francisella cf.novicida Fxl (Francisella cf.novicida Fx l), Alicyclobacillus acidoterrestris (Alicyclobacillus acidoterrestris), Oleiphilus s p.), bacteria CC09 39 24, Deltaproteobacteria bacteria, or known PAM The vector may be derived from any species that encodes a CRISPR nuclease having the sequence Bacterially encoded CRISPR nucleases may also be used in the context of the present invention. (See Burstein et al. Nature, 2017). spC as9 D1135E variant, spCas9 VQR variant, spCas9 E Contains a known PAM sequence, such as a QR variant or spCas9 VRER variant Variants of CRISPR proteins may also be used in the context of the present invention.

[0219] Therefore, Cas9 proteins, modified Cas9s, Cas9 homologs or orthologs RNA-guided DNA nucleases, or CRISPR systems, such as Other types of CRISPR systems, such as pfl and its homologs and orthologs Other RNA-guided DNA nucleases may be used in the compositions of the invention. stomach.

[0220] In certain embodiments, the CRISPR nuclease is a naturally occurring Cas protein. A "functional derivative" of a native sequence polypeptide may be a "functional derivative" of a native sequence polypeptide. It is a compound that has qualitative biological characteristics in common with the sequence polypeptide. "Antibody" includes any polypeptide that possesses biological activity in common with the corresponding native sequence polypeptide. , fragments of native sequences and derivatives of native sequence polypeptides and fragments thereof Biological activities contemplated herein include, but are not limited to: The functional derivative is the ability to hydrolyze the DNA substrate into fragments. , both amino acid sequence variants of the polypeptide, covalent modifications thereof and fusions thereof. Suitable derivatives or fragments of the Cas polypeptide include the Cas protein. Protein variants, fusions, covalent modifications or fragments thereof are included, but Cas proteins, including but not limited to Cas proteins or fragments thereof. Derivatives of the Cas protein and Cas protein or fragments thereof are available from cells. They may be obtained by chemical synthesis or by a combination of these two methods. The cell may be a cell that naturally produces a Cas protein. or naturally produce Cas proteins and produce endogenous Cas proteins at high expression levels. or an exogenously introduced nucleic acid encoding a Cas that is the same or different from the endogenous Cas. The cells may be genetically engineered to produce Cas proteins from In this case, the cell does not naturally produce Cas proteins, but They are genetically modified to live.

[0221] In some embodiments, the CRISPR nuclease is Cpfl. l was guided by a single RNA utilizing a T-rich protospacer adjacent motif Cpfl is an endonuclease that opens DNA by creating a staggered double-strand break. Cleavage. From the genera Acidaminococcus and Lachnospiraceae Two Cpfl enzymes have been demonstrated to have efficient genome editing activity in human cells. (See Zetsche et al. (2015) Cell.)

[0222] Therefore, the Cas9 protein or modified Cas9 or a Cas9 homolog, or RNA-guided DNA of type II CRISPR systems, such as solologs or variants nuclease or other nucleases, such as Cpfl and its homologs, orthologs or variants. Other RNA-guided DNA nucleases belonging to the CRISPR system are May be used in the specification.

[0223] In some embodiments, the guide molecule is one that adds new or improved properties. or multiple chemical modifications (e.g., improved stability from degradation, improved hybrid energy) or improved binding properties with RNA-guided DNA nucleases). Chemical modifications include, but are not limited to, modified bases, modified sugar moieties, or modified internucleoside linkages. Non-limiting examples of suitable chemical modifications include 4-acetylcytidine, 5-(carboxyhydroxymethyl)uridine, 2'-O-methylcytidine, 5-carbo 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluridine Dihydrouridine, 2'-O-methylpseudouridine, β, D-galactosyl Guanosine, 2'-O-methylguanosine, inosine, N6-isopentenyl adenosine 1-methyladenosine, l-methylpseudouridine, l-methylguanosine, 1- Methylinosine, "2,2-dimethylguanosine", 2-methyladenosine, 2-methyl Guanosine, 3-methylcytidine, 5-methylcytidine, N6-methyladenosine, 7- Methylguanosine, 5-methylaminomethyluridine, 5-methoxyaminomethyl-2- Thiouridine, "β, D-mannosylqueosine", 5-methoxycarbonylmethyl- 2-thiouridine, 5-methoxycarbonylmethyluridine, 5-methoxyuridine, 2 -Methylthio-N6-isopentenyladenosine, N-((9-β-D-ribofuranosyl -2-methylthiopurin-6-yl)carbamoyl)threonine, N-((9-β-D- Ribofuranosylpurin-6-yl)N-methylcarbamoyl)threonine, uridine-5 -hydroxyacetic acid methyl ester, uridine-5-hydroxyacetic acid, wybutoxosine, Queuosine, 2-thiocytidine, 5-methyl-2-thiouridine, 2-thiouridine, 4-thiouridine, 5-methyluridine, N-((9-β-D-ribofuranosylpurine 6-yl)-carbamoyl)threonine, 2'-O-methyl-5-methyluridine, 2' -O-methyluridine, wybutosin, 3-(3-amino-3-carboxy-propyl ) Uridine, (acp3)u, 2'-O-methyl (M), 3'-phosphorothioate ( MS), 3'-thioPACE (MSP), pseudouridine or 1-methylpseudouridine Each possibility represents a separate embodiment of the present invention.

[0224] Further non-limiting examples of suitable chemical modifications include m 1 A (1-methyladenosine), m 2 A(2-methyladenosine); Am(2'-O-methyladenosine); ms 2 m 6 A (2-methylthio-N 6 -methyladenosine);i 6 A(N 6 -Isopentenyl adenosine nn);ms 2 i6A(2-methylthio-N 6Isopentenyladenosine);io 6 A(N 6 -(cis-hydroxyisopentenyl)adenosine);ms 2 io 6 A(2-methylthio O-N 6 -(cis-hydroxyisopentenyl)adenosine);g 6 A(N 6 -Grissini Glycinylcarbamoyladenosine );t 6 A(N 6 -threonylcarbamoyl adenosine);ms 2 t 6 A(2-methylthio O-N 6 -threonylcarbamoyl adenosine);m 6 t 6 A(N 6 -methyl-N 6 -vinegar leonylcarbamoyl adenosine);hn 6 A(N 6 -hydroxynorvalylcarbamoyl adenosine);ms 2 hn 6 A(2-methylthio-N 6 -hydroxynorvalylcarba Ar(p)(2'-O-ribosyladenosine (phosphate)); I( Inosine);m 1 I(l-methylinosine);m 1 Im(l,2'-O-dimethylino n);m 3 C(3-methylcytidine); Cm(2'-O-methylcytidine); s 2 C(2 -thiocytidine);ac 4 C(N 4 -acetylcytidine);f 5 C(5-formylcytidine) n);m 5 Cm(5,2'-O-dimethylcytidine);ac4 Cm(N 4 -acetyl-2 '-O-methylcytidine);k 2 C(lycidin);m 1 G(l-methylguanosine); m 2 G(N 2 -methylguanosine);m 7 G(7-methylguanosine); Gm(2'-O -methylguanosine);m 2 2G(N 2 ,N 2 -dimethylguanosine);m 2 Gm(N 2 、2’ -O-dimethylguanosine);m 2 2Gm(N 2 ,N 2 ,2'-O-trimethyl Guanosine; Gr(p) (2'-O-ribosylguanosine (phosphate)); yW (Wibb Tosin); 02 yW (peroxywybutosin); OHyW (hydroxywybutosin) ;OHyW* (unmodified hydroxywybutosin);imG (wiosin);mimG (me Chilwiosin; Q (queuosin); oQ (epoxyqueuosin); galQ (gal lactosylqueosine; manQ (mannosylqueosine); preQ o (7- Cyano-7-deazaguanosine; preQ1 (7-aminomethyl-7-deazaguanosine) NG);G + (Archaeosin); D(Dihydrouridine); m 5 Um(5,2'-O-dimethyl thyluridine);s 4 U(4-thiouridine);m 5 s 2 U(5-methyl-2-thiouric acid Jin);s 2 Um(2-thio-2'-O-methyluridine); acp 3 U(3-(3-A (amino-3-carboxypropyl)uridine);ho 5 U(5-hydroxyuridine);m o 5 U(5-methoxyuridine); cmo 5 U(uridine 5-oxyacetic acid);mcmo 5 U(uridine 5-hydroxyacetic acid methyl ester);chm 5 U(5-(carboxyhydroxy Dimethyluridine 5 U(5-(carboxyhydroxymethyl)uridine methyl ester);mcm 5 U(5-methoxycarbonylmethyluridine); mcm 5 U m(5-methoxycarbonylmethyl-2'-O-methyluridine); mcm 5 s 2 U(5 -Methoxycarbonylmethyl-2-thiouridine);nm 5 S 2 U(5-aminomethyl- 2-thiouridine);mnm 5 U(5-methylaminomethyluridine); mnm 5 s 2 U (5-methylaminomethyl-2-thiouridine); mnm 5 se 2 U(5-methylamino Methyl-2-selenouridine);ncm 5 U(5-carbamoylmethyluridine);nc m5Um (5-carbamoylmethyl-2'-O-methyluridine); cmnm5U (5- Carboxymethylaminomethyluridine; cmnm5Um (5-carboxymethylaminomethyluridine) 2'-O-methyluridine; cmmm5s2U (5-carboxymethylamine) Dimethyl-2-thiouridine; Dimethyladenosine; Im(2'-O-methylinosine) m4C (N4-methylcytidine); m4Gm (N4,2'-O-dimethylcytidine) );hm5C (5-hydroxymethylcytidine);m3U (3-methyluridine);cm 5U (5-carboxymethyluridine); m6Am (N6,2'-O-dimethyladenosine) m62Am(N6,N6,0-2'-trimethyladenosine); m2'7G(N2 ,7-dimethylguanosine; m2,2,7G (N2,N2,7-trimethylguanosine );m3Um(3,2'-O-dimethyluridine);m5D(5-methyldihydrouridine) f5Cm(5-formyl-2'-0-methylcytidine); m1Gm(l,2'-0 -dimethylguanosine); m'Am(l,2'-0-dimethyladenosine); xm5U( 5-Taurinomethyluridine; xmVU (5-Taurinomethyl-2-thiouridine)) imG-l4 (4-demethylwiosin); imG2 (isowiosin); or ac6 A (N6-acetyladenosine). Each possibility represents a separate embodiment of the present invention. (See U.S. Patent No. 9,750,824).

[0225] Guide sequences that specifically target mutant alleles A given gene may contain thousands of SNPs. To target each SNP in a gene, Using a 24 base pair targeting window would require hundreds of thousands of guide sequences. Any given guide sequence when used to target a SNP will However, the guide sequence may be degraded, have limited or no activity, or have off-target effects. Therefore, appropriate guide sequences are required to target certain genes. The present invention allows the expression of mutant proteins to be knocked out and the ELANE gene to be expressed. Guide sequences for inactivating mutant alleles in children and treating SCN or CyN A novel set of genes was identified.

[0226] The present disclosure provides a method for inactivating mutant alleles while leaving functional alleles unmodified. The guide sequences of the present invention provide a guide sequence that can be specifically targeted for the purpose of designed and capable of specifically distinguishing between heterologous and functional alleles It is most effective to select all possible genes that target the mutant allele that you want to inactivate. Among the guide sequences, the specific guide sequences disclosed in the present invention are It is particularly effective at functioning in

[0227] Briefly, guide sequences are used to: (1) identify individuals in the general population, specific ethnic groups, or patient populations; Prevalence of >1% and SNP / insertion / deletion / indel heterozygosity in the same population (2) Target heterozygous SNPs / insertions / deletions / indels with a prevalence of >1%; For example, 5 kb of DNA can be extracted from any part of a gene, such as the promoter, UTR, exon, or intron. Targeting the location of a SNP / insertion / deletion / indel proximal to a portion of a gene, such as within a base pair, (3) Using RNA molecules that target founder or common pathogenic mutations for a disease / gene. In some embodiments, the gene may have the property of targeting mutant alleles using a nucleotide sequence. Prevalence of SNPs / insertion / deletions / indels in the general population, specific ethnic groups, or patient populations are 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12% , 13%, 14% or 15% of SNPs / insertion / deletion / inferiority in the same population The rates of ligation are 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, and 11%. , 12%, 13%, 14%, or greater than 15%. Each possibility represents a separate embodiment, and They may be combined at will.

[0228] For each gene, mutant alleles were identified according to SNP / insertion / deletion / indel. A knockout strategy that uses a single RNA molecule to activate CRIS PR nuclease is targeted to the mutant allele to create a double-strand break (DSB), which then targets the mutant allele. To create a frameshift mutation in an exon or splice site region of an allele, (2) knockout strategies using two RNA molecules The first RNA molecule encodes a region within the promoter of the mutant allele. Alternatively, another RNA molecule targets the upstream region of the mutant allele, and the promoter of the mutant allele is (3) targeting downstream of the first RNA molecule within a promoter, exon, or intron; Intron(s) skipping strategy - The 5th intron is skipped to destroy the splice site. Splicing either the 1' end (donor sequence) or the 3' end of the intron (acceptor sequence) A single RNA molecule is used to target CRISPR nuclease to the region of the target site. Any one of the following strategies may be used. Alternatively, the first RNA molecule may be The first RNA molecule targets the upstream region of the first RNA molecule, and the second RNA molecule targets the downstream region of the first RNA molecule. Two RNA molecules may be used to excise the exon(s). Based on the location of the SNP / insertion / deletion / indel identified for each mutant allele, any one or combination of the above methods for inactivating the mutant allele. may be used.

[0229] When only one RNA molecule is used, the location of the SNP must be within an exon or Very close (e.g., within 20 base pairs) to a splice site between an intron and an exon When two RNA molecules are used, the guide sequence is Exon 1, such as within the translated region, within the promoter, or the first 2 kilobases 5' of the transcription start site The second SNP is located upstream of the transcription start site in the first 2 kilobases 5' of intron 1, two SNPs downstream of the first SNP, such as within exons 2 or 3 or within exons 1, 2 or 3; SNPs may also be targeted.

[0230] The guide sequence of the present invention is a sequence located upstream of a target gene, preferably upstream of a target gene. The guide sequence may target a SNP upstream of the last exon. flow, e.g., within the 5' untranslated region, within the promoter, or the first 4-5 km 5' of the transcription start site SNPs within the base may be targeted.

[0231] The guide sequences of the present invention also identify known protospacer adjacent motif (PAM) sites. SNPs that are very close (within 50 base pairs, more preferably within 20 base pairs, etc.) may be targeted. stomach.

[0232] The guide sequences of the present invention also identify (1) heterozygous SNPs in the targeted gene; (2) heterozygous SNPs in the targeted gene; (3) heterozygous SNPs upstream and downstream of genes, and (4) populations, specific ethnic groups, or patient populations SNPs with SNP / insertion / deletion / indel prevalence >1%, (4) guanidine - Cytosine content is greater than 30% but less than 85%, (5) 4 or more thymine / uracil (6) No repeat sequences or 8 or more repeat sequences of guanine, cytosine, or adenosine; (7) preferably without off-targets identified by targeted analysis; targeting exons rather than exons, or upstream of the SNP rather than downstream of the SNP. It may also be a target.

[0233] In an embodiment of the present invention, the SNP may be upstream or downstream of the gene. In one embodiment, the SNP is within 4,000 base pairs upstream or downstream of the gene.

[0234] At least one nucleotide that differs between the mutant allele and the functional allele is It may be upstream, downstream or internal to the disease-causing mutation sequence of the gene of interest. At least one nucleotide that differs between the gene and the functional allele of interest It may be within an exon or an intron of the gene. , at least one nucleotide that differs between the mutant allele and the functional allele is Within an exon of the gene of interest. In some embodiments, the mutant allele At least one nucleotide that differs between the functional allele and the gene of interest within an exon or intron, i.e., a spiracle between an intron and an exon Very close to the splice site, e.g., splice sites 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 nucleotides It is located upstream or downstream.

[0235] In some embodiments, at least one nucleotide is a single nucleotide polymorphism (SNP In some embodiments, each of the nucleotide variants of the SNP is In some embodiments, the SNPs are founder or allelically expressed. It may also be a common pathogenic variant.

[0236] Guide sequences are used to identify: (1) a high prevalence in the population, such as >1% of the population; (2) targeting SNPs with high heterozygosity rates in the population, e.g., greater than 1%; The guide sequence may target a SNP distributed worldwide. In some embodiments, the mutation may be a founder or common pathogenic mutation in a population. The prevalence in %, 12%, 13%, 14% or greater than 15%. Each possibility represents a separate embodiment. In some embodiments, the heterozygosity rate in a population is 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, %, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14% or more than 15% Each possibility represents a separate embodiment.

[0237] In some embodiments, the minimum difference between the mutant allele and the functional allele is At least one nucleotide is associated with a disease-causing mutation that is highly prevalent in the population. In such embodiments, "high prevalence" means at least 92% , 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%. Each variant allele and each variant represent separate embodiments of the present invention. At least one nucleotide that differs between the disease-causing allele and the disease-causing allele is a disease-causing mutation. In some embodiments, the SNP is highly prevalent in the population. In terms of morphology, "highly prevalent" means at least 10%, 11%, or 12% of the population. , 13%, 14%, 15%, 20%, 30%, 40%, 50%, 60% or 70% Each possibility represents a separate embodiment of the present invention.

[0238] The guide sequences of the present invention may meet any one of the above criteria and may be used to target mutant alleles. This is most likely to distinguish it from the corresponding functional allele.

[0239] In some embodiments, the RNA molecule is derived from a SNP as shown in Table 1 below. The target is a heterozygous SNP in the ELANE gene. Details of the SNP are shown from the left. The first column contains the SNP ID (NCBI 2018 database of single nucleotide polymorphisms). For variants without rs numbers, The characteristics of the second browser are shown based on the gnomAD 2018 browser database. The first column shows the identifier assigned to each SNP. The third column shows the The position of each SNP on the gene is shown. [Table 1]

[0240] Figure 5 discloses the heterogeneity of certain SNPs selected from Table 1 in human populations. do.

[0241] An embodiment of the present invention is a sequence encoding a sequence from upstream of the SNP position to intron 3, intron 4, or 3'UT. In one embodiment, the first The guide sequence is a specific sequence of a heterozygous SNP in the upstream region of the mutant allele (strategy 1a-rs104l4837, strategy 1b-rs376l005) and the second guideline The nucleotide sequence targets a sequence in intron 4 that is common to the two alleles of the gene (Figure 1). In a further embodiment, the first guide sequence is a heterologous sequence in the upstream region of the mutant allele. Specific sequences of the zygotic SNPs (Strategy 1a - rs10414837, Strategy 1b - rs37 The second guide sequence targets an interferon-like molecule common to the two alleles of the gene. In another embodiment, the first guide sequence targets the sequence in intron 3. Specific sequence of heterozygous SNP in the upstream region of the gene (Strategy 1a - rs104l4837 , strategy 1b-rs376l005), and the second guide sequence targets two pairs of genes. It targets a sequence in the 3'UTR common to alleles (Figure 2).

[0242] An embodiment of the present invention is a sequence from intron 3, intron 4 or 3'UTR to the bottom of the 3'UTR. In one embodiment, the first guide array comprises: Specific sequence of heterozygous SNP position in the upstream region of the mutant allele (Strategy 2-rs16 The second guide sequence targets the amino acid sequence common to the two alleles of the gene. In a further embodiment, the first guide sequence targets the sequence of thrombin 4. Specific sequence of heterozygous SNP position in the upstream region of the allele (Strategy 2 - rs16835 64), and the second guide sequence is an intron common to the two alleles of the gene. In a further embodiment, the first guide sequence targets the sequence of the mutant allele. Specific sequence of heterozygous SNP position in the upstream region of the offspring (Strategy 2 - rs1683564) The second guide sequence is a sequence in the 3'UTR common to the two alleles of the gene. (Figure 3).

[0243] An embodiment of the present invention is a sequence from intron 3, intron 4 or 3'UTR to the bottom of the 3'UTR. This strategy leaves the healthy allele intact while excising the disease-causing allele. They are designed to specifically knock out the disease-causing allele (the "mutant allele"). Allele-specific editing distinguishes between heterozygous and heterozygous individuals with relatively high heterozygous frequencies in the population (heterozygotes). This is achieved by using guides that target the SNP locations (Figure 4).

[0244] Cellular delivery In an exemplary method, the RNA molecules and compositions described herein are administered to any It is understood that delivery to a target cell or subject may be by any suitable means. provides non-limiting examples of methods for delivering the RNA molecules and compositions of the present invention.

[0245] In some embodiments, the RNA molecules and compositions of the present invention can be used in any mammalian or plant cell line. Any cell containing and / or expressing a dominant negative allele, including human cells For example, in one embodiment, the RNA molecule may target a mutant ELANE The allele is specifically targeted and the target cells are hepatocytes.

[0246] Any suitable uveitis may be used to deliver the nucleic acid compositions, such as the RNA molecule compositions, of the subject invention. Viral vector systems may be used. Conventional viral or non-viral based Gene transfer methods can be used to transfer nucleic acids and target tissues. In embodiments, the nucleic acid is administered in in vitro or ex vivo gene therapy applications. Viral vector delivery systems include naked nucleic acid and liposome or poloxamer delivery. The nucleic acid complexed with the vehicle is included. (1992)Science 256:808-813, Nabel & Feigne r(1993)TIBTECH 11:211-217, Mitani & Caske y(1993)TIBTECH 11:162-166, Dillon(1993)TI BTECH 11:167-175, Miller (1992) Nature 357: 455-460, Van Brunt (1988) Biotechnology 6(1 0):1149-1154, Vigne (1995) Restorative Neurology ology and Neuroscience 8:35-36, Kremer & Perricaudet (1995)British Medical Bulletin n 51(1):31-44, Haddada et al. (1995) in Cur rent Topics in Microbiology and Immunolo gy Doerfler and Bohm (eds.) and Yu et al. (1 994) See Gene Therapy 1:13-26.

[0247] Non-viral methods for delivery of nucleic acids and / or proteins include electroporation , lipofection, microinjection, gene gun, particle gun accelerator, virosome , liposomes, immunoliposomes, lipid nanoparticles (LNPs), polycations or lipids: nuclei There are drug-enhanced uptake of acid complexes, artificial virions and nucleic acids, or bacteria or viruses ( Agrobacterium, Rhizobium spp., NGR234, Sinorhizoboiummeli loti, Mesorhizobium loti, Tobacco mosaic virus, Mussels mosaic virus X, cauliflower mosaic virus, and cassava vein mosaic virus, etc.) (Chung et al. (2006) Tre nds Plant Sci.1 l(l):l-4, etc.). Sonitron 2 Sonoporation using the 000 system (Rich-Mar) etc. Can be used to deliver nucleic acids. Cationic nature of proteins and / or nucleic acids Lipid-mediated delivery is also contemplated as an in vivo or in vitro delivery method. See t al.(2015) Nat.Biotechnol.33(l):73-80 ; Coelho et al. (2013) N.Engl.J.Med.369, 81 9-829; Judge et al. (2006) Mol. Ther. 13, 494 -505; and Basha et al. (2011) Mol. Ther. 19, 218 See also 6-2200.)

[0248] Further representative nucleic acid delivery systems include Amaxa® Biosystems ms (Cologne, Germany), Maxcyte, Inc. (Rockville, Md.), BTX Molecular Delivery Systems (Holliston, Mass.) and and Copernicus Therapeutics Inc. (See, for example, U.S. Patent No. 6,008,336.) Lipofection is described in U.S. Patent No. 5,629,663. ,049,386, U.S. Pat. No. 4,946,787 and U.S. Pat. No. 4,897,35 Lipofection reagents are commercially available (Transfect am™, Lipofectin™ and Lipofectamine™ Suitable for efficient receptor-recognition lipofection of polynucleotides. Cationic and neutral lipids include those described by Feigner, WO91 / 17424, WO9 Delivery can be to cells (ex vivo administration) or target tissues (in vivo administration). This can be done for (given).

[0249] The preparation of lipid:nucleic acid complexes, including targeted liposomes such as immunolipid complexes, is well within the skill of the art. It is well known (Crystal (1995) Science 270:404-410; B laese et al. (1995) Cancer Gene Ther.2:291-297;B Ehr et al. (1994) Bioconjugate Chem. 5:382-389; Re My et al. (1994) Bioconjugate Chem. 5:647-654; Gao (1995) Gene Therapy 2:710-722; Ahmad et al. (199 2) Cancer Res. 52:4817-4820; U.S. Patent No. 186,183; No. 4,217,344, No. 4,235,871, No. 4,261,975, No. 4,4 No. 85,054, No. 4,501,728, No. 4,774,085, No. 4,837,0 (See, e.g., Nos. 28 and 4,946,787).

[0250] An additional delivery method involves incorporating the nucleic acid to be delivered into an EnGeneIC delivery vehicle (EDV). These EDVs are packaged in a way that allows one arm of the antibody to bind to the target cell. and EDV specificity to target cells. The antibody carries the EDV to the surface of the target cell, where it is then delivered intracellularly. Once inside the cell, the contents are released. (MacDiarmid et al. (2009) Nature Biotechnology 2 7(7):643).

[0251] Using RNA or DNA virus-based systems for virally mediated delivery of nucleic acids This targets the virus to specific cells in the body and delivers the viral payload to the nucleus. Utilizing a highly evolved process for administering viral vectors directly to patients Alternatively, the cells can be engineered in vitro and the engineered cells administered to a patient. It can also be used in vivo (ex vivo). These include retroviral vectors, lentiviral vectors, and adenoviral vectors for gene transfer. vectors, adeno-associated virus vectors, vaccinia vectors and herpes simplex vectors Examples of such devices include, but are not limited to:

[0252] Retroviral tropism can be altered by incorporating heterologous envelope proteins This allows for the expansion of the potential target population of target cells. Viral vectors transduce or infect non-dividing cells and generally produce high viral titers. Retroviral vectors that can induce gene transfer. The choice of vector depends on the target tissue. Retroviral vectors can be used to express heterologous vectors up to 6-10 kb. The minimal cis-acting LT consists of cis-acting terminal repeats capable of packaging the nucleotide sequence. R is sufficient to replicate and package the vector, which then integrates the therapeutic gene into the target cell. It is used to provide sustained transgene expression by embedding the cells in the cells. As virus vectors, murine leukemia virus (MuLV) and gibbon ape leukemia virus (GV) are used. GaLV, Simian immunodeficiency virus (SIV), Human immunodeficiency virus (HIV) and and combinations thereof (e.g., Buchschacher et al. (1992) ) J. Virol. 66:2731-2739; Johann et al. (1992) J. Virol. ol.66:1635-1640;Sommerfelt et al. (1990) Virol.1 76:58-59;Wilson et al. (1989) J. Virol.63:2374-23 78;Miller et al. (1991) J.Virol.65:2220-2224;PCT / US94 / 05700 etc.).

[0253] At least six viral vector approaches are currently available in clinical trials. Gene insertion into the Luper cell line complements the defective vector to produce transducing agents. Use techniques that include:

[0254] pLASN and MFG-S are retroviral vectors that have been used in clinical trials. Examples of this are (Dunbar et al. (1995) Blood 85:3048-305; Ko hn et al. (1995) Nat Med. 1:1017-102; Malech et al. (1997 )PNAS94:2212133-12138). PA317 / pLASN is a gene therapy It was the first therapeutic vector used in a therapeutic trial (Blaese et al., 1995). Transduction efficiencies of over 50% were observed for vectors packaged in MFG-S. (Ellem et al. (1997) Immunol Immunother.44(1):10 -20; Dranoff et al. (1997) Hum. Gene Ther. 1:111-2) .

[0255] The packaging cells produce viral particles that can infect host cells. These cells include 293 cells that package adenovirus, AAV. These cells contain Psi-2 cells or PA317 cells that package retroviruses. Viral vectors used in gene therapy are usually nucleic acid vectors that are incorporated into viral particles. This vector is typically produced by a packaging producer cell line. and contain the minimal viral sequences required for subsequent integration into the host (if applicable). Other viral sequences are replaced by expression cassettes encoding the proteins to be expressed. The missing viral functions are supplied in trans by the packaging cell line. For example, AAV vectors used in gene therapy are generally packaged in Inverted terminal sequences (ITAs) from the AAV genome are required for the AAV to bind and integrate into the host genome. The viral DNA is packaged in a cell line that contains only the AAV gene. a helper plus gene encoding rep and cap but lacking ITR sequences The cell line is also infected with a helper adenovirus. Virus promotes AAV vector replication and AAV gene expression from helper plasmids The helper plasmid lacks ITR sequences and is therefore not packaged in significant amounts. Contamination with adenovirus is prevented by heat treatment, to which adenovirus is more sensitive than AAV. Furthermore, AAV can be produced using a baculovirus system. The method can be produced on a clinical scale using the methods described in US Pat. No. 7,479,554.

[0256] In many gene therapy applications, gene therapy vectors are highly targeted to specific tissue types. Therefore, it is desirable to deliver a viral vector with high specificity. The antibody protein expresses the ligand as a fusion protein on the outer surface of the virus. By using this ligation, the specificity of the target gene can be improved to a certain cell type. The strand is chosen to have affinity for a receptor known to be present on the cell type of interest. For example, Han et al. (1995) Proc. Natl. Acad. Sci. US A92:9747-9751, a human leukemia virus (HV) clone fused to gp70 The recombinant virus can be modified to express human epidermal growth factor γ-α, ... It has been reported that the virus infects certain human breast cancer cells that express the receptor. The cell expresses the receptor, and the virus expresses a fusion protein containing a ligand for the cell surface receptor. This can be extended to other virus-target cell pairs that express the same protein. For example, filamentous phagocytic leukemia virus (FPV) The antibody has specific binding affinity for a receptor on virtually any selected cell. The above description is primarily focused on viruses. Although this applies to viral vectors, the same principles can be applied to non-viral vectors. Such vectors can be used to target specific uptake vectors that favor uptake by specific target cells. It can be manipulated to contain sequences.

[0257] Gene therapy vectors are administered to individual patients, typically systemically (e.g., intravitreally, intravenously) In vivo by local administration, such as intraperitoneal, intramuscular, subcutaneous, or intracerebral injection) or as described above. Alternatively, the vectors can be delivered to cells explanted from an individual patient (e.g., lymphocytes, bone marrow aspiration, cell biopsy, etc.) or universal donor hematopoietic stem cells, These can be delivered in a single dose and subsequently administered to the patient, usually after selecting cells that have integrated the vector. Re-implant the cells.

[0258] for diagnostics, research, or gene therapy (e.g., reinfusion of transfected cells into a host organism); Ex vivo cell gene transfer (via transfection) is well known to those skilled in the art. In this embodiment, cells are isolated from a subject organism, transfected with a nucleic acid composition, and the cells are transformed into a target organism. The various cell types suitable for ex vivo gene transfer are well known to those skilled in the art. Knowledge (e.g., Freshney et al. (1994) Culture of Animals l Cells, A Manual of Basic Technique, 3rd ed and the references cited therein for discussing methods for isolating and culturing cells from patients. (See bibliography).

[0259] Suitable cells include, but are not limited to, eukaryotic cells and / or cell lines. Non-limiting examples of such cells or cell lines made from such cells include: , COS, CHO (e.g. CHO-S, CHO-K1, CHO-DG44, CHO-D UXB11, CHO-DUKX, CHOK1SV, etc.), VERO, MDCK, WI38, V79, B14AF28-G3, BHK, HaK, NSO, SP2 / 0-Agl4, He La, HEK293 (e.g., HEK293-F, HEK293-H, HEK293-T etc.), perC6 cells, any plant cell (differentiated or undifferentiated), and Spod Insect cells such as Saccharomyces, Pichia, and In certain embodiments, the cell line is a CHO- K1, MDCK, or HEK293 cell lines. Furthermore, primary cells can be isolated and treated. Reintroduce a guided nuclease system (e.g., CRISPR / Cas) into the patient Suitable primary cells include peripheral blood mononuclear cells, and may be used ex vivo to treat PBMCs, and CD4+ T cells or CD8+ T cells, etc., but not limited to these. Suitable cells also include, by way of example, embryonic stem cells. , induced pluripotent stem cells, hematopoietic stem cells (CD34+), neural stem cells and mesenchymal stem cells There are cells.

[0260] In one embodiment, stem cells are cultured ex vivo for cell transfection and gene therapy. The advantage of using stem cells is that they can be differentiated into other cell types in vitro. can be transformed into a mammalian cell, or introduced into a mammal (such as a cell donor) where it will engraft in the bone marrow. It is possible to use cytokines such as GM-CSF, IFN-γ, and TNF-α. There are currently no known methods for differentiating CD34+ cells in vitro into clinically important immune cell types. (See, for example, non-limiting examples, Inaba et al., J. Exp. Med. 176:1693-17 02(1992)).

[0261] Using known methods, stem cells are isolated for transduction and differentiation. For example, CD4 + and CD8+ (T cells), CD45+ (panB cells), GR-1 (granulocytes) and la Panning of bone marrow cells using antibodies that bind to unwanted cells such as differentiated antibody-presenting cells (APCs) Stem cells are isolated from bone marrow cells by performing a non-limiting procedure (see, for example, Inaba et al. (1999) 992) J. Exp. Med. 176:1693-1702). Some embodiments In some embodiments, already modified stem cells may be used.

[0262] Generally, the cells are administered in a pharmaceutical composition that includes at least one pharmaceutically acceptable carrier. The phrase "pharmaceutically acceptable" means within the bounds of good medical common sense and without excessive toxicity. , without irritation, allergic reactions, or other problems or complications, and with a reasonable benefit / risk ratio Compounds, substances and compositions suitable for use in contact with human and animal tissues The phrase "pharmaceutically acceptable carrier" as used herein refers to a composition and / or dosage form. When the substance is encapsulated, the pharmaceutically acceptable liquid, solid filler, diluent, excipient, or solvent is used. "Contains" means a substance, composition or medium in which

[0263] Any one of the RNA molecule compositions described herein may be expressed in post-mitotic cells or is suitable for genome editing in any cell that is not actively dividing, e.g., an arrested cell. Post-mitotic cells that can be edited using the RNA molecule compositions of the present invention Examples of cells include, but are not limited to, hepatocytes.

[0264] A vector (e.g., retrovirus, liposome, etc.) containing the therapeutic nucleic acid composition is delivered in vivo. They can also be administered directly to an organism to transduce cells in vivo. Including, but not limited to, topical administration (e.g., eye drops and creams) and electroporation It is not intended to introduce molecules into ultimate contact with blood or tissue cells. Suitable methods for administering such nucleic acids are known to those skilled in the art. are widely available and well known, and may use more than one route to administer a particular composition. Yes, but certain routes often provide a more immediate and effective response than others. According to some embodiments, the composition is delivered by IV injection.

[0265] Suitable vectors for transgene delivery into immune cells (e.g., T cells) include non-integrating vectors. Antiviral vectors are included. See U.S. Patent Application Publication No. 2009-0117617. Illuminate.

[0266] Pharmaceutically acceptable carriers will vary depending on the particular composition being administered and the nature of the agent by which the composition is administered. This is determined in part by the particular method used to As such, there are a wide variety of suitable formulations of pharmaceutical compositions available (see Remington's s Pharmaceutical Sciences, 17th ed., 1989 etc. (See

[0267] According to some embodiments, the RNA-guided DNA nuclease binds / associated and / or RNA-guided DNA nucleases of the gene of interest At least one nucleotide (S) differs between the mutator and the functional allele. NP) (e.g., sequences of mutators that are not present in functional alleles) The sequence may be within a disease-associated mutation. The mutation may be upstream or downstream of the disease-associated mutation. Any sequence differences between the two will preserve the activity of the functional allele, while the RNA molecules of the present invention otherwise, the dominance of the mutant allele is reduced. These proteins may be targeted to neutralize their disease-causing effects.

[0268] The disclosed compositions and methods also include administering a drug to treat a dominant genetic disorder in a patient. It may be used in the manufacture of

[0269] Mechanism of Action for Some Embodiments Disclosed herein Mutations in ELANE that have been shown to cause SCN or CyN result in truncated N-terminal proteins. Translation of alternatively oriented ORFs to generate proteins This mediates ER and protein misfolding stress.

[0270] Without wishing to be bound by any theory or mechanism, the present invention is Applying CRISPR nucleases to mutate genes to prevent, ameliorate, or treat CyN Prevent expression of the pathogenic ELANE allele or cleave it from the mutated pathogenic allele Creating non-pathogenic peptides or repairing / correcting mutated pathogenic ELANES. , process mutated pathogenic ELANE alleles but not functional ELANE alleles It is used to avoid

[0271] Several different editing strategies were applied that utilize SNPs located upstream or downstream of the ORF. Strategies include removal of the entire gene, truncation of the gene to remove the C-terminus of the gene, and This includes amplification and attenuation of gene expression.

[0272] In some embodiments, two guides (such as those disclosed in Table 2) are inserted into the entire gene. Knockout of mutant protein by removing exons (i.e., exons 1, 2, 3, 4, and 5) In some embodiments, the first guide RNA may be By targeting the SNP / WT sequence located upstream of the ORF of the mutant allele of the ANE gene, and the second guide RNA utilized to mediate allele-specific DSBs by EL SNP located in exon 5 of the ANE gene or downstream of the mutant allele / WT sequence, or located in intron 4, 3' UTR or downstream of an allele of the ELANE gene or located in intron 4, 3'UTR or downstream of an allele of the ELANE gene The SNP may be utilized to mediate a DSB in the corresponding SNP / WT sequence.

[0273] A frameshift mutation resulting in the acquisition of a stop codon located in exon 3 Therefore, a possible strategy is to target exons 1 to 3 at most. In some embodiments, the mutant allele may be truncated to include up to 1000 nucleotides. In this study, two guides (such as those disclosed in Table 2) were used to identify the variant alleles of the ELANE gene. In some embodiments, the first Guide RNAs are targeted to exon 5 of the mutant allele or downstream SNP / WT sequences. A second guide RNA may be utilized to mediate allele-specific DSBs by A is a sequence located in intron 1, 2 or 3 of the ELANE gene or a SNP / WT sequence The truncated mutant allele may be used to mediate DSBs. The peptide / protein may not have a pathogenic effect or may be a nonsense-mediated The expression of the mutant allele may be knocked out by triggering the mRNA degradation machinery. Results may be verified by examining mRNA and protein expression.

[0274] In some embodiments, expression of the mutant allele is determined by a SNP located upstream of the ORF. by excising elements from the proximal promoter and enhancer regions using In a non-limiting example, an enhancer region may be attenuated by targeting a SNP. By ablating most of the area, a significant reduction may be achieved. An example of an RNA guide sequence that specifically targets a mutant allele of the ELANE gene

[0275] Although many guide sequences can be designed to target mutant alleles, The nucleotide sequences set forth in Table 2, identified by the following SEQ ID NOs: 1 to 1192, are In order to effectively carry out the methods described herein and to effectively differentiate between alleles, were specifically selected to differentiate between the two.

[0276] Referring to columns 1 to 4, each of SEQ ID NOs: 1 to 1192 shown in column 1 is a sequence of The corresponding SNP details are shown in column 2. The SNP details shown in the columns are assigned to each SNP corresponding to the SNP ID shown in Table 1. Column 3 shows the ELAN identifiers assigned to each guide sequence at the target site. Column 4 indicates whether the E gene is polymorphic or wild-type. The guanine-cytosine content of the columns is indicated.

[0277] Table 2 shows the above-described embodiments in relation to different SNPs within the variant ELANE allele sequence. The figures show guide sequences designed for use as described in the embodiments. Guide molecules may also be designed to match the sequence NGG or NAG (where "N" is any nucleobase). A target of interest located adjacent to a protospacer adjacent motif (PAM), such as a PAM The guide sequence is designed to be associated with the target genomic DNA sequence. (PAM SEQ:NGG), SpCas9.VQR.l(PAM SEQ:NGAN) , SpCas9.VQR.2(PAM SEQ:NGNG), SpCas9.EQR(P AM SEQ:NGAG), SpCas9.VRER(PAM SEQ:NGCG), S aCas9WT(PAM SEQ:NNGRRT), NmCas9WT(PAM SEQ :NNNNGATT), Cpfl(PAM SEQ:TTTV) or JeCas9WT( PAM SEQ:NNNVRYM) and other similar terms. The RNA of the present invention was designed to function in combination with a CRISPR nuclease. Each molecule combines with one or more different CRISPR nucleases to form a complex. Each CRISPR nuclease is designed to generate a single or multiple Designed to target polynucleotide sequences of interest using a variety of PAM sequences will be done. [Table 2-1] [Table 2-2] [Table 2-3] Table 2-4 Table 2-5 Table 2-6 Table 2-7 Table 2-8 Table 2-9 Table 2-10 Table 2-11 Table 2-12 Table 2-13 Table 2-14 Table 2-15 Table 2-16 Table 2-17 Table 2-18 Table 2-19 Table 2-20 Table 2-21 Table 2-22 Table 2-23 Table 2-24 Table 2-25 Table 2-26 Table 2-27 Table 2-28 Table 2-29 Table 2-30 Table 2-31

[0278] For the foregoing embodiments, each embodiment disclosed herein may be used in conjunction with any other disclosed embodiment. For example, any RNA molecule or composition of the present invention may be used in the methods of the present invention. It is understood that any method of the invention may be utilized.

[0279] As used herein, all headings are for organizational purposes only and do not affect any The disclosure is not intended to be limiting in any way. may be equally applicable to all paragraphs.

[0280] In order to facilitate a more complete understanding of the present invention, the following examples are provided. The present invention will now be described with reference to exemplary modes of making and practicing the present invention. It is not intended to be limiting to the specific embodiments disclosed in these examples, which are for illustrative purposes only. The purpose is to

[0281] Further, the following examples of the present invention disclose SpCas9 and SpCas9. Disclosed are methods that involve utilizing guide sequences suitable for directing to SNP locations. The examples demonstrate the feasibility of the disclosed strategies. Those skilled in the art will be able to apply each of the specific strategies. The same guide sequence can be used with different CRISPR nucleases for It will be understood that the SNPs shown may also be targeted. To apply this, we will use different guides to target other CRISPR nucleases to the same SNP. The sequence may also be used in conjunction with other nucleases. [Example]

[0282] Experimental details Example 1: SNP-targeting guide sequences suitable for functioning in combination with SpCas9 Arrays and screening sequences according to the strategy disclosed HeLa cells were seeded in a 96-well plate (3K / well). After 24 hours, the cells were incubated at 65°C. ng WT-Cas9 or Dead-Cas9 and identified as g36 to g66. Different regions of ELANE were cultured using rbofect reagent (Thermo Scientific). and SNP-targeting gRNA plasmid (20 ng). Fresh medium was added, and 72 hours after transfection, genomic DNA was extracted and Ca The predicted region targeted by s9 was amplified and the product size was compared with that of the DNA ladder. The band intensities were analyzed using Peak Scanner software. Analysis was performed using ware vl.0. The percentage of editing was calculated according to the following formula: 100% - (unedited band intensity / total band intensity) x 100. Figure 6 shows the results of three independent experiments. The average activity of each gRNA after subtracting the experimental Dead-Cas9 background activity ± S Represents D.

[0283] [Table 3]

[0284] Example 2: Proving the feasibility of the resection strategy HeLa cells were co-transfected with spCas9-WT and RNA pairs. sg35(INT4) and g39(rs104l4837) for a, lb and 2, respectively ), g58 (rs376l005) or g62 (rs1683564). 72 hours after transfection, gDNA was extracted and analyzed using the droplet digital PC R (ddPCR) kit (10042958 and 10031228, Bio-Rad Laboratories) Using a lab-based assay, the copy number of exon 1 (Strategy 1) or exon 5 (Strategy 2) was determined. The resection efficiency was evaluated by measuring the reduction in the number of serotonin-dependent ATPases. exon 1 was used to normalize the excision rate for strategy 1, whereas exon 5 was used to normalize the excision rate for strategy 2. The results disclosed in Table 4 show the mean % resection ± SD (standard deviation) of two independent experiments. show.

[0285] [Table 4]

[0286] Example 3: Distinguishing between editing by different sgRNAs to evaluate alleles Ribonucleoprotein complexes (RNPs) targeting the reference sequence according to the manufacturer's instructions Constructed from the relevant gRNAs, WT-Cas9 (#1081058) or HiF iCas9 (#1081060) Integrated DNA Technology RNPs were then transferred to iPSCs harboring the relevant SNPs. Nucleofect (n) using the D-Nucleofecor® system (Lonza) After 72 hours, gDNA was extracted and the SNP region was amplified. The alleles were then subjected to NGS analysis. Allele discrimination was detected between the reference allele and the alternative allele. The indel frequency at each site was evaluated using Cas-Analyzer. The software was used to calculate the results, which are summarized in Table 5.

[0287] [Table 5]

[0288] Example 4: Editing efficiency in HSCs HSCs from healthy donors were transfected with spCas9-WT and EMX1 (sgEMXl) or EL ANE(g35:INT4;g58:rs376l005;g62:rs1683564 ) were nucleofected with the RNA components of gRNA targeting either 72 hours after nucleofection, gDNA was extracted and analyzed for editing levels. The ATP was quantified by IDAA. Figure 7 shows the results of two independent experiments performed in duplicate. The mean % edit ± SD is shown.

[0289] Example 5: Functional Maturation Assay Patient-derived induced pluripotent stem cells to demonstrate phenotypic rescue in corrected cells A maturation assay starting from iPSCs was prepared from reprogrammed somatic cells. These cells provide a renewable source of patient-derived cells and can accurately recapitulate disease phenotypes. Briefly, patient PBMCs were transfected with Oct4, Sox2, Nanog, and Li. expressing the reprogramming genes n28, L-Myc, Klf4, and SV40LT. Patient-derived iPSCs with identical SNP genotypes are transfected with episomal constructs. and normal iPSCs were cultured using a commercially available kit (STEMdiff™ Hematopoie Hematopoietic progenitor cells were isolated using a cytotoxic kit (STEMCELL Technologies). After 12 days, differentiation efficiency was assessed by flow cytometry analysis of progenitor cell markers. Estimated by analyzing cells for expression of CD34 and CD45. N-differentiated progenitor cells were gene-edited to express stem cell factor (SCF), IL-3, and neutrophil-specific genes. The cells were grown for 5 days in a conditioned medium containing GM-CSF, which promotes differentiation. The cells that were edited, i.e., the SCN-edited cells, differentiated into neutrophils, while the unedited SCN The differentiation efficiency of neutrophils was evaluated by flow cytometry. Ligands containing neutrophil surface markers (e.g., CD16, CD66b, and the pan-myeloid marker CD33) were used. It is measured by detecting the level of expression (e.g., increased expression).

[0290] Example 6: In vivo dose ranging and biodistribution pilot study in immunodeficient mice Self-renewal and multilineage potential in immunodeficient NSG mice after administration of G-CSF The dosing schedule, dose range, and administration method for determining the presence and number of potent HSCs Study pathways that can regenerate a functional immune system to establish long-term engraftment. A repopulation assay is performed to measure the presence and number of SCs. The NSG cell line, which is highly supportive of human engraftment and hematopoietic repopulation, is used. In addition to defects in multiple cytokine signaling pathways and numerous defects in innate immunity, , NOD SCID, which lacks mature T cells, B cells, and natural killer (NK) cells Mice. Engraftment is assessed 16 weeks after primary transplantation (analysis 12 weeks post-transplantation).

[0291] A 16-week biodistribution pilot study in NSG mice showed that the dose and maximum duration The study will be conducted at several cell dose levels, examining the effect of 3 dose levels. The pilot study will include a group of mice receiving unedited SCN cells and a group of mice receiving unedited SCN cells. The treatment period is six weeks, but one of the two higher dose groups will continue for up to six months. In the pilot study, mice survived for 6 months, and the duration of the core biodistribution study was 6 months. During this study, persistence of expression will be investigated by qPCR and immunohistochemistry.

[0292] Example 7: Central biodistribution studies in immunodeficient mice The central biodistribution study utilized NSG mice and included the pilot dose range of Example 6. This study was conducted in compliance with Good Laboratory Practices (GLP) and was conducted in a central non-clinical setting. The study included pharmacokinetic, pharmacodynamic, and toxicological studies. The toxicity studies included mortality, clinical outcomes, and mortality after HSC infusion. Based on findings, body and organ weights, and clinical and anatomic pathology.

[0293] To engraft gene-edited CD34+ cells into NSG mice, endogenous bone marrow depletion was required. Pretreatment is required to provide the donor cells and allow them to engraft. Busulfan pretreatment was used to mimic the condition. Ten male and female mice were used per group. Three groups of mice (gene-edited cells, unedited cells, and busulfan vehicle only) Use the control.

[0294] Although the NSG mouse model does not fully resemble the human neutrophil-depleted situation, All proportions of mice were treated with Busulfo before in vivo injection of ex vivo gene-edited cells. This study aims to investigate the in vivo function of gene-edited CD34+ cells by treating them with an anti-CD34 antibody to deplete bone marrow function. Neutrophil-deficient mouse strains available do not affect the validity of the model for use in distribution studies. , Lyz2 Cre / Cre Mcl-l flox / flox (Mcl-l ΔMyelo )of Myeloid cell leukemia (Mcl-1) anti-apoptotic protein, Mcl-1 is a myeloid cell It is known that specific deficiency leads to very severe neutropenia (Csepregi et al., 2018). Mcl-l ΔMyelo Mice can reproduce and their survival rate is Specific pathogen-free conditions and conventional However, in contrast to NSG mice, Mcl- 1 ΔMyelo There is limited experience with mouse models.

[0295] Example 8: Modification Analysis A sequence of 17 to 20 adjacent nucleotides set forth in SEQ ID NOs: 1 to 1192 Guide sequences containing 17-20 nucleotides in the sequence were screened for high activity on the target. On-target activity is measured by DNA capillary electrophoresis analysis. .

[0296] According to DNA capillary electrophoresis analysis, the 1 sequences set forth in SEQ ID NOs: 1 to 1192 were A group containing 17-20 nucleotides in a sequence of 7-20 adjacent nucleotides The id sequence is found to be suitable for the modification of the ELANE gene.

[0297] Example 9: Efficacy of allele-specific knockout of ELANE Specific knockout of the mutant allele of the ELANE gene This is mediated by excising intron 4 and exon 5 of the allele. DSB in intron 4 to mediate allele-specific DSB as depicted in Figure 8 This is achieved by utilizing SNPrs1683564 as a mediator. To demonstrate that HSCs can efficiently differentiate into mature and functional neutrophils in the presence of Healthy donors were then treated with g35 and g40 targeting each SNP in intron 4 (see Table 1). Nucleofect with HSC (Lonza) containing RNP containing g62. Unedited cells are used as a positive control. Forty-eight (48) hours after injection, the mice were treated according to published protocols (Zhenwang Jie et al., 2014). HSCs were differentiated into neutrophils according to the method described in osOne 2017. The edited and unedited cells were then differentiated into neutrophils. The differentiation efficiency of the collected cells was evaluated after staining with neutrophil-specific markers CD66b and CD177. To assess HSC-mediated neutrophil function as measured by ACS, perform the following assays: Execute. 1. Phagocytosis using the EZCell™ Phagocytosis Assay Kit ( The assay is performed using a flow cytometer (BioVision). as a tool for rapid and accurate detection and quantification of phagocytosis in vitro. The purified zymosan particles are used. 2. HSC-derived neutrophils were cultured with E. coli and then the bacteria were plated on agar plates for colony formation. Killing assays are performed by seeding untreated bacteria or undifferentiated HSCs. Bacteria cultured with and are used as controls. The killing efficiency is calculated as follows: Ronnie number Neutrophils / colony count コントロール )x100. 3.EZCell(trademark) Cell Migration / Chemotaxis A Chemotaxis is assayed using a chemotaxis assay kit (Biovision).

[0298] Example 10: Patient Selection for Treatment Step 1: Four patients, A to D, diagnosed with SCN or CyN were subjected to exon sequencing. Screening is performed to identify ELANE pathogenic variants in the ELANE gene. Step 2: Subjects with identified mutations are then Sanger sequenced to identify rs168 Heterozygosity for at least one of 3564, rs104l4837, and rs376l005 Step 3: RS1683564, RS104L48 For each subject determined to be heterozygous for at least one of rs37 and rs376l005 The nucleotides of the heterozygous SNPs of the mutant alleles in the ELANE gene are: Determine using BAC bio. Step 4. Select appropriate guide according to Table 6 do. [Table 6]

[0299] Step 5. Transduce selected guides into PBMCs obtained from each subject and then transfer them to PBMCs Next-generation sequencing was used to verify the reduction of pathogenic ELANE mutations in C. Patient A The methodology for ∼D is described below. 1. Patient A is selected according to step 1 and is consistent with the phenotype and clinical situation; Patient A has a known pathogenic variant in ELANE. ,Selected according to step 2, three SNPrs10414837, rs16835 Patient A was found to be homozygous for all of rs376l005 and rs64. It is deemed not suitable. 2. Patient B is tested for known pathogenic ELANE mutations. Patient B is then referred to Step 2. Therefore, we selected the mutants homozygous for SNPrs1683564 and rs104l4837. Patient B is heterozygous for rs376l005 in the promoter region. Patient B is deemed suitable for treatment. ... Determine the nucleotides present in the same allele as the ELANE mutation (linkage determination). Subject B had a SNP at rs3761005 on the same allele as the ELANE pathogenic variant. g58ref is completely consistent with the presentation of this SNP. It is complemented by g35, which is directed to the non-coding region of intron 4. According to Step 4, the guide composition selected was the pair of guides g58ref and g35. Was the excision of the mutated allele using this selected guide pair successful? Validate according to step 5 using NGS reads on patient PMBCs. 3. Patient C has suffered from severe neutropenia since early childhood. Patient C was selected for the treatment and no pathogenic mutation was found in the ELANE gene. I decide not to. 4. Patient D is verified to have a known pathogenic mutation in the ELANE gene and proceeds to Step 2. Therefore, when the SNPs were genotyped, two of the three SNPs were heterozygous. This means that both rs104l4837 and rs1683564 are heterozygous. rs3761005 is found to be homozygous. To make the selection, perform step 3. Perform a genomic DNA analysis to determine the linkage between the SNP and the pathogenic variant, i.e., the SNP (reference or surrogate) Determine which nucleotides are present on the same allele as the ELANE pathogenic variant ( SNP presentation). Patient D was determined to have a reference presentation of rs10414837, and sg39re f is deemed appropriate for use. Referring to the rs1683564 SNP, the alternative presentation is , which has been found to be associated with ELANE pathogenic mutations, and sg62al Use each of these guides in conjunction with the g35. Following step 4, two pairs of possible guide compositions, sg39ref+g3 5 and g62alt+g35 to determine which guide pair is preferred. Then, a database of editing characteristics and features of each guide and guide pair is evaluated to determine the Determine the acquisition effect and editing efficiency. Select guide pairs based on database evaluation. Follow step 5 to utilize the PMBC provided NGS reads. TIFF2024160277000038.tif237166 TIFF2024160277000039.tif237166 TIFF2024160277000040.tif244167 TIFF2024160277000041.tif129166

Claims

1. Cellular, severe congenital neutropenia (SCN) or cyclic neutropenia (CyN)-associated Mutations in the neutrophil elastase gene (ELANE gene) A method for inactivating a gene, the cell comprising: 76l005, rs1683564, rs9749274, rs74002l, rs20 l048029, rs199720952, rs28591229, rs7l33527 6, rs58082l77, rs3826946, rs10413889, rs76l4 8l944, rs376l008, rs10409474, rs3761007, rs1 72l6649, rs10469327, rs8l07095, rs10424470 and and rs78302854. The method further comprises: The cells, CRISPR nuclease or a sequence encoding said CRISPR nuclease, and Beauty a first RNA molecule comprising a guide sequence portion having 17 to 20 nucleotides; introducing a composition; The complex of the CRISPR nuclease and the first RNA molecule is affecting a double stranded break in said mutant allele of a gene.

2. The complex of the CRISPR nuclease and the first RNA molecule is affecting a double strand break in said mutant allele of the NE gene, said mutant allele comprising:

13. The method of claim 1, wherein the nucleic acid sequence is targeted for double-strand breaks based on the one or more polymorphic sites. The method according to

3. A second nucleic acid sequence comprising a guide sequence portion capable of forming a complex with a CRISPR nuclease. The method further comprises introducing an RNA molecule, wherein the second RNA molecule and the CRISPR nuclease are The complex of α-aminotransferases affects a second double-stranded break in the ELANE gene. The method according to claim 1 or claim 2.

4. The guide sequence portion of the first RNA molecule is any one of SEQ ID NOs: 1 to 1192. Any of claims 1 to 3, comprising 17 to 20 contiguous nucleotides as set forth.

13. The method according to claim 1.

5. The second double-stranded break is within a non-coding region of the ELANE gene.

5. The method according to claim 4.

6. The cells are heterozygous at rs10414837 or rs3761005, The complex of the second RNA molecule and the CRISPR nuclease is The method according to any one of claims 3 to 5, which affects a double-stranded break in intron 4 of the gene. Law.

7. The cells are heterozygous for rs10414837 or rs3761005, The complex of the second RNA molecule and the CRISPR nuclease is The method according to any one of claims 3 to 5, which affects a double-stranded break in intron 3 of the gene. Law.

8. The cells are heterozygous for rs10414837 or rs3761005, The complex of the second RNA molecule and the CRISPR nuclease is The method according to any one of claims 3 to 5, which affects double-strand breaks in the 3'UTR region of the gene. method.

9. The cell is heterozygous at rs1683564, and the second RNA molecule and The RISPR nuclease complex is located in intron 4 of the ELANE gene. The method according to any one of claims 3 to 5, which affects double-strand breaks.

10. The cell is heterozygous at rs1683564, and the second RNA molecule and The RISPR nuclease complex is located in intron 3 of the ELANE gene. The method according to any one of claims 3 to 5, which affects double-strand breaks.

11. The cell is heterozygous at rs1683564, and the second RNA molecule and The complex of RISPR nuclease binds to the 3′UTR region of the ELANE gene. The method according to any one of claims 3 to 5, wherein the method affects double-strand breaks.

12. ELANE gene mutations associated with severe congenital neutropenia (SCN) or CyN The cells having the mutation are treated with an ELANE gene mutation associated with SCN or CyN. and / or from a subject suffering from SCN or CyN, said subject , rs10414837, rs3761005, rs1683564, rs974927 4, rs740021, rs201048029, rs199720952, rs285 91229, rs71335276, rs58082177, rs3826946, rs 10413889, rs761481944, rs3761008, rs1040947 4, rs3761007, rs17216649, rs10469327, rs8107 rs10424470 and rs78302854 The method according to any one of claims 1 to 11, wherein the gene is heterozygous at one or more polymorphic sites.

13. First, have an ELANE gene mutation associated with SCN or CyN; and / or Selecting a subject suffering from SCN or CyN, said subject having an rs1041 4837, rs3761005, rs1683564, rs9749274, rs740 021, rs201048029, rs199720952, rs28591229, r s71335276, rs58082177, rs3826946, rs1041388 9, rs761481944, rs376l008, rs10409474, rs376 l007, rs172l6649, rs10469327, rs8107095, rs1 One or more polymorphisms selected from the group consisting of rs78302854 and rs0424470 the subject is heterozygous at the site, and obtaining the cell from the subject. The method according to claim 12.

14. Obtaining said cells from said subject by mobilization and / or by apheresis. The method of claim 13 or 14, comprising:

15. The method of claim 14, further comprising obtaining the cells from the subject by bone marrow aspiration. method.

16. 16. The method according to claim 1, wherein the cells are pre-stimulated before the composition is introduced into the cells.

3. The method according to claim 1 .

17. The method according to any one of claims 12 to 16, further comprising culturing and growing the cells to obtain a cell population.

3. The method according to claim 1 .

18. The cells are treated with one or more of stem cell factor (SCF), IL-3, and GM-CSF. The method of claim 17, wherein the culture is performed together with

19. 19. The method according to claim 17 or 18, wherein the cells are cultured with at least one cytokine. Method of posting.

20. 20. The method of claim 19, wherein the at least one cytokine is a recombinant human cytokine. The method described.

21. The cell is one of a plurality of cells, and the first RNA molecule or the first and and administering the composition comprising both of the first and second RNA molecules to at least one of the cells in the plurality of cells. and other cells, and Inactivating the mutant allele of the ELANE gene in a cell, thereby The method according to any one of claims 1 to 20, wherein the mutant cells are obtained.

22. Introducing the composition comprising the first RNA molecule or introducing the second RNA molecule The method according to any one of claims 1 to 21, wherein the introduction comprises electroporation of the cell or cells.

3. The method according to claim 1 .

23. 23. A modified cell obtained by the method of claim 21 or 22.

24. 22. A modified cell obtained by culturing and growing the cell of claim 21.

25. 25. The modified cell or cells of claim 23 or 24, capable of engraftment.

26. 26. The modified cell of any one of claims 23 to 25, which is capable of giving rise to progeny cells, or Multiple engineered cells.

27. 27. The modified cell or modified cells of claim 26, which are capable of giving rise to progeny cells after engraftment. cell.

28. 28. The modified cell or cells of claim 27, which are capable of giving rise to progeny cells after autologous transplantation. Modified cells.

29. capable of giving rise to progeny cells for at least 12 months or at least 24 months after engraftment 29. The modified cell or cells according to claim 27 or 28.

30. The modified cell or cells are hematopoietic stem and / or progenitor cells (HSPCs).

30. The modified cell or cells according to any one of claims 23 to 29.

31. 31. The method of claim 30, wherein the modified cell or cells are CD34+ hematopoietic stem cells. The modified cell or cells.

32. The modified cell or cells are bone marrow cells or peripheral mononuclear cells (PMCs).

32. The modified cell or cells of any one of claims 23 to 31.

33. A modified cell lacking at least a portion of one allele of the ELANE gene.

34. The modified cells include rs10414837, rs3761005, rs1683564, rs9749274, rs74002l, rs20l048029, rs1997209 52, rs2859l229, rs7l335276, rs58082l77, rs38 26946, rs104l3889, rs76l48l944, rs376l008, r s10409474, rs376l007, rs172l6649, rs1046932 7, rs8107095, rs10424470 and rs78302854 The method of claim 1, further comprising:

34. The modified cell according to claim 33.

35. A method for producing a modified cell comprising the steps of: composition.

36. 36. The method of claim 35, comprising mixing the cells with the pharma- ceutically acceptable carrier. In vitro or ex vivo methods for preparing the compositions.

37. 1. A method for preparing a composition comprising modified cells in vitro or ex vivo, said method comprising: teeth, a) Having an ELANE gene mutation associated with SCN or CyN and / or S By isolating HSPCs from a plurality of cells obtained from a subject suffering from CN or CyN, wherein the subject has rs104l4837, rs376l005, rs1683564 , rs9749274, rs740021, rs201048029, rs199720 952, rs28591229, rs7l335276, rs58082l77, rs3 826946, rs104l3889, rs76148l944, rs376l008, rs10409474, rs3761007, rs17216649, rs104693 The group consisting of 27, rs8l07095, rs10424470 and rs78302854 and said subject is heterozygous at one or more polymorphic sites selected from obtaining said cells from the b) inactivating said mutant allele of said ELANE gene in one or more cells. to the cells of step (a) to induce CRISPR nuclease or a sequence encoding said CRISPR nuclease, and Beauty a first RNA molecule comprising a guide sequence portion having 17 to 20 nucleotides; Introducing a composition, The complex of the CRISPR nuclease and the first RNA molecule comprises one or more affecting a double-stranded break in the mutant allele of the ELANE gene in a cell; Optionally, the cell can be complexed with a CRISPR nuclease. Introducing a second RNA molecule comprising a guide sequence portion, and a CRISPR nuclease, affecting a second double-strand break in the gene, thereby obtaining a modified cell; and optionally c) culturing and growing the modified cells of step (b); The method, wherein the modified cells are capable of engrafting and giving rise to progeny cells after engraftment.

38. a) Having an ELANE gene mutation associated with SCN or CyN and / or S By isolating HSPCs from a plurality of cells obtained from a subject suffering from CN or CyN, wherein the subject has rs104l4837, rs376l005, rs1683564 , rs9749274, rs740021, rs201048029, rs199720 952, rs28591229, rs7l335276, rs58082l77, rs3 826946, rs104l3889, rs76148l944, rs376l008, rs10409474, rs3761007, rs17216649, rs104693 The group consisting of 27, rs8l07095, rs10424470 and rs78302854 being heterozygous at one or more polymorphic sites selected from b) inactivating said mutant allele of said ELANE gene in one or more cells. to the cells of step (a) to induce CRISPR nuclease or a sequence encoding said CRISPR nuclease, and Beauty a first RNA molecule comprising a guide sequence portion having 17 to 20 nucleotides; Introducing a composition, The complex of the CRISPR nuclease and the first RNA molecule comprises one or more affecting a double strand break in the mutant allele of the ELANE gene in a cell; Optionally, the cell can be complexed with a CRISPR nuclease. Introducing a second RNA molecule comprising a guide sequence portion, and a CRISPR nuclease, affecting a second double-strand break in the gene, thereby obtaining a modified cell; and optionally c) culturing the cells of step (b), wherein the modified cells engraft. and capable of giving rise to progeny cells after engraftment; and d) administering step (b) to the subject to treat the SCN or CyN in the subject; or administering the cells of step (c). Use of the composition.

39. A therapeutically effective amount of the modified cell according to any one of claims 21 to 34, the combination according to claim 35, Administering a composition or a composition prepared by the method of claim 36 or 37. A method for treating a subject suffering from SCN or CyN, comprising:

40. Subjects in need of treatment who have an ELANE gene mutation associated with SCN or CyN A method for treating SCN or CyN in a subject, the subject having rs10414837, rs10414837, rs10414837, s376l005, rs1683564, rs9749274, rs74002l, rs 20l048029, rs199720952, rs2859l229, rs7l335 276, rs58082177, rs3826946, rs104l3889, rs76 l481944, rs376l008, rs10409474, rs3761007, r s172l6649, rs10469327, rs8l07095, rs1042447 Heterozygous at one or more polymorphic sites selected from the group consisting of rs78302854 and rs78302854. and the method further comprises: a) isolating HSPCs from a plurality of cells obtained from the subject; b) inactivating said mutant allele of said ELANE gene in one or more cells. to the cells of step (a) to induce CRISPR nuclease or a sequence encoding said CRISPR nuclease, and Beauty a first RNA molecule comprising a guide sequence portion having 17 to 20 nucleotides; Introducing a composition, The complex of the CRISPR nuclease and the first RNA molecule comprises one or more affecting a double strand break in the mutant allele of the ELANE gene in a cell; Optionally, the cell can be complexed with a CRISPR nuclease. Introducing a second RNA molecule comprising a guide sequence portion, and a CRISPR nuclease, affecting a second double-strand break in the gene, thereby obtaining a modified cell; and optionally c) culturing the cells of step (b), wherein the modified cells engraft. and capable of giving rise to progeny cells after engraftment; and d) administering to said subject said cells of step (b) or step (c), thereby Treating the SCN or CyN in the subject.

41. Subjects in need of treatment who have an ELANE gene mutation associated with SCN or CyN A method for treating SCN or CyN in a subject, the subject having rs10414837, r s3761005, rs1683564, rs9749274, rs740021, rs 201048029, rs199720952, rs28591229, rs71335 276, rs58082177, rs3826946, rs10413889, rs76 1481944, rs3761008, rs10409474, rs3761007, r s17216649, rs10469327, rs8107095, rs1 04244 rs70 and rs78302854. and the method further comprises: administering to said subject autologous modified cells or progeny of said autologous modified cells, The mutant cells are modified to produce a double-stranded break in the mutant allele of the ELANE gene. Changed, The double-stranded break is caused by a CRISPR nuclease or a introducing into said cell a composition comprising a coding sequence and a first RNA molecule, The complex of the CRISPR nuclease and the first RNA molecule is said mutant allele of said ELANE gene being inactivated; affecting a double strand break in the mutant allele, thereby pre-infecting said subject. The method of treating SCN or CyN.

42. A method for selecting a subject for treatment from a pool of subjects diagnosed with SCN or CyN. So, a) obtaining cells from each subject in said pool of subjects; b) screening cells from each subject for ELANE gene mutations associated with SCN or CyN; Selecting only subjects with ELANE gene mutations associated with SCN or CyN 、 c) sequencing the cells of the subject selected in step (b) s104l4837, rs376l005, rs1683564 selecting for heterozygosity at one or more polymorphic sites; and d) administering to a subject having cells that are heterozygous at said one or more polymorphic sites for treatment. selecting only the first and second vertices.

43. e) removing the erythrocyte from said subject's bone marrow by aspiration or by mobilization and apheresis of peripheral blood; Obtaining hematopoietic stem and progenitor cells (HSPCs) by any of the following methods; f) the HSPC cells of step (e) One or more CRISPR nucleases or one or more CRISPR nucleases ase-encoding sequence The one or more polymorphic sites present in the mutant allele of the ELANE gene. SEQ ID NOs: 1-119 targeting the nucleotide bases of the heterozygous alleles at positions 2. A sequence of 17 to 20 contiguous nucleotides as set forth in any one of claims 1 to 2. a first RNA molecule comprising a guide sequence portion having 17-20 nucleotides; and A sequence in intron 3, intron 4 or 3'UTR of the ELANE gene and introducing a second RNA molecule comprising a guide sequence portion that targets the The complex of the first RNA molecule and the CRISPR nuclease comprises one or more of the At the first double-strand break in the mutant allele of the ELANE gene in HSPC cells and the complex of the second RNA molecule and the CRISPR nuclease is Before the complex of the NA molecule and the CRISPR nuclease affects a first double-stranded break. Intron 3 of both alleles of the ELANE gene in one or more HSPC cells; affecting a second double-stranded break in intron 4 or the 3′ UTR, thereby modifying the cells To obtain, g) administering to the subject the modified cells of step (f), thereby causing SCN in the subject. or treating CyN, and further treating SCN or CyN in the subject selected in step (d). The method of claim 42, further comprising:

44. 17 to 20 adjacent amino acids set forth in any one of SEQ ID NOs: 1 to 1192 RNA containing a guide sequence portion having 17 to 20 nucleotides in the nucleotide sequence. molecule.

45. A composition comprising the RNA molecule of claim 44 and a second RNA molecule comprising a guide sequence portion. thing.

46. The second RNA molecule targets a non-coding region of the ELANE gene.

45. The composition described in 45.

47. The nucleotide sequence of the guide sequence portion of the second RNA molecule is 45 or 46. The method of claim 45, wherein the guide sequence portion of the A molecule is a nucleotide sequence different from the sequence of the A molecule.

47. The composition according to claim 46.

48. The first and / or second RNA molecule further binds a CRISPR nuclease. The composition according to any one of claims 45 to 47, comprising a portion having a sequence corresponding to

49. The sequence that binds to the CRISPR nuclease is a tracrRNA sequence. Item 49. The composition according to item 48.

50. The first and / or second RNA molecules further comprise a portion having a tracr mate sequence. The composition according to any one of claims 45 to 48, comprising:

51. The second RNA molecule further comprises one or more linker portions.

13. The composition according to any one of claims 1 to 12.

52. the first and / or second RNA molecule is up to 300 nucleotides in length; A composition according to any one of claims 42 to 51.

53. One or more CRISPR nucleases or the one or more CRISPR nucleases A sequence encoding a tracrase, and / or one or more tracrRNA molecules, or Any of claims 45 to 52 further comprising a sequence encoding a tracrRNA molecule or a plurality of tracrRNA molecules. The composition according to any one of claims 1 to 4.

54. 1. A method for inactivating a mutant ELANE allele in a cell, the method comprising: The cell is administered with an RNA molecule according to claim 44 or a combination according to any one of claims 45 to 53. The method comprises delivering the composition.

55. A method for treating SCN or CyN, the method comprising administering to a subject having SCN or CyN, In particular, the RNA molecule according to claim 44 or the composition according to any one of claims 45 to 53. or the RNA molecule according to claim 44 or any one of claims 45 to 53. delivering a cell modified by the composition.

56. The one or more CRISPR nucleases and / or the tracrRNA molecules and and administering said RNA molecule or RNA molecules to said subject and / or cell substantially simultaneously.

56. The method of claim 54 or 55, wherein the administration is at the same time or at different times.

57. The method comprises: a) removing an exon containing a disease-causing mutation from a mutant allele, The first RNA molecule or the first and second RNA molecules may comprise an entire exon or targeting a region adjacent to a portion of an exon; b) removing multiple exons, entire open reading frames of genes; or removing the entire gene; c) the first RNA molecule or the first and second RNA molecules are mutant alleles Targeting alternative splicing signal sequences between exons and introns of the offspring 、 d) the second RNA molecule is present at both the mutant allele and the functional allele. Targeting the sequence; e) the second RNA molecule targets an intron; f) Insertion into the mutant allele by an error-prone non-homologous end joining (NHEJ) mechanism inserting or deleting a gene that is a mutant allele of a gene that is a mutated allele of a target gene, Including, Optionally, the frameshift is an inactivation or knockout of the mutant allele. This gives rise to Preferably, the frameshift results in a premature stop codon in the mutant allele. A nonsense mutation is created in the transcript of the mutant allele by the frameshift. The method according to any one of claims 54 to 56, wherein a dependent mRNA degradation mechanism occurs.

58. The inactivation or treatment results in a truncated protein encoded by the mutant allele. and a functional protein encoded by said functional allele.

58. The method according to any one of claims 5 to 57.

59. a) the cell or the subject is heterozygous for rs104l4837 or rs376l005; and wherein the complex of the second RNA molecule and a CRISPR nuclease is affecting a double-stranded break in intron 4 of the ELANE gene, b) the cell or the subject is heterozygous for rs104l4837 or rs376l005; and wherein the complex of the second RNA molecule and a CRISPR nuclease is affecting a double-stranded break in intron 3 of the ELANE gene, c) the cell or the subject is heterozygous for rs104l4837 or rs376l005; and wherein the complex of the second RNA molecule and a CRISPR nuclease is affecting a double-strand break in the 3'UTR region of the ELANE gene; d) the cell or the subject is heterozygous at rs1683564 and the second The complex of the RNA molecule and the CRISPR nuclease is Affects double-strand breaks in intron 4, e) the cell or the subject is heterozygous for rs1683564 and the second The complex of the RNA molecule and the CRISPR nuclease is Affects double-strand breaks in intron 3, f) the cell or the subject is heterozygous for rs1683564 and the second The complex of the RNA molecule and the CRISPR nuclease is a 3′ sequence of the ELANE gene. 'A method according to any one of claims 55 to 58, which affects double-strand breaks in the UTR region. Law.

60. 45. The RNA of claim 44 for inactivating a mutant ELANE allele in a cell. A molecule, a composition according to any one of claims 35, 45 to 53 or claims 36 or 37.

2. Use of a composition prepared by the method according to claim 1.

61. 45. The method of claim 44 for use in inactivating a mutant ELANE allele in a cell. The RNA molecule, the composition according to any one of claims 35 or 45 to 53, or claim 36 37. A drug comprising a composition prepared by the method according to claim 37, 45. The RNA molecule according to claim 44, or the composition according to any one of claims 35 or 45 to 53. or by delivering a composition prepared by the method of claim 36 or 37. Administering the drug.

62. Treating SCN or CyN in a subject having or at risk of having SCN or CyN The method according to any one of claims 1 to 22, claims 23 to 26 for the treatment, amelioration or prevention of 34, the modified cell according to any one of claims 35 or 45 to 53. or a composition prepared by the method according to claims 36-37, or a composition according to claim 44. The use of the RNA molecules described.

63. 45. The RNA molecule of claim 44 for use in treating, ameliorating or preventing SCN or CyN. The composition according to any one of claims 35 or 45 to 53, the composition according to claim 36 or 37 A composition prepared by the method described above or a modified cell according to any one of claims 23 to 34. A drug comprising the compound according to claim 1, wherein the compound is administered to a subject having or at risk of having SCN or CyN. 44, the composition according to any one of claims 35 or 45 to 53, 36 or 37, or a composition prepared by the method according to any one of claims 23 to 34. The drug is administered by delivering the modified cells described in item 1.

64. 45. The RNA molecule, CRISPR nuclease or CRISPR of claim 44. A sequence encoding a nuclease and / or a tracrRNA molecule or the tracrRNA molecule a sequence encoding rRNA and a sequence encoding a mutant ELANE allele that inactivates the mutant ELANE allele in the cell; In order to do so, the RNA molecule, the CRISPR nuclease or the CRISPR nuclease A sequence encoding a tracrase, and / or the tracrRNA molecule or the tracr and a mutant E1 gene encoding a sequence for delivering RNA to said cell. A kit for inactivating the LANE allele.

65. 45. The RNA molecule, CRISPR nuclease or CRISPR of claim 44. A sequence encoding a nuclease and / or a tracrRNA molecule or the tracrRNA molecule A sequence encoding rRNA and the RNA molecule, CR, for treating SCN or CyN. A sequence encoding an ISPR nuclease or said CRISPR nuclease, and / or or a tracrRNA molecule or a sequence encoding said tracrRNA, or CyN, A kit for treating SCN or CyN in a subject.

66. The composition according to any one of claims 35 or 45 to 53, claim 36 or 37 or a modification according to any one of claims 23 to 34. a cell, and administering said composition to said cell so as to inactivate said ELANE gene in said cell. and instructions for delivering to said cell a mutant ELANE allele that is inactivating said cell. Kit for.

67. The composition according to any one of claims 35 or 45 to 53, claim 36 or 37 or a modification according to any one of claims 23 to 34. Cells and any one of claims 35 or 45 to 53 for treating SCN or CyN A composition according to claim 36 or 37, a composition prepared by the method according to claim 37 or a composition according to claim 39. The modified cell according to any one of claims 23 to 34, which has or has SCN or CyN. and instructions for delivering the same to a subject at risk of developing SCN or CyN. A kit for

Citation Information

Patent Citations

  • Crispr / CAS9-based treatments

    WO2017004616A1

  • Methods and compositions for modulating gene expression

    WO2018049073A1